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Programmed death ligand-1 (PD-L1) expression in various cancers including head and neck 
cancer favors cancer cell survival and proliferation as it allows them to escape the immune 
system. PD-L1 binds to its receptor at the surface of cytotoxic tumor infiltrating T cells (CD8+ 
TILs). and induces an inhibitory signaling pathway that interferes with T cell activation after 
specific antigen recognition through the T cell receptor. Blocking this negative pathway by 
preventing ligand-receptor interactions with an antibody is a Nobel Prize-winning powerful 
emerging tool in immunotherapy and frequently associated to conventional treatment strategies. 
Beyond PD-L1 expression, cancer cells are also capable of polarizing tumor-associated 
macrophages (TAMs) towards a M2-like phenotype, which adds several immunosuppressive 
properties to the tumor microenvironment and induces inactivation or even apoptosis of tumor 
infiltrating lymphocytes. It has been shown that radiotherapy can be used to repolarize 
macrophages from a M2 towards a M1-like immuno-stimulating phenotype. Furthermore, X-
ray irradiation induces an increased PD-L1 expression in cancer cells through the activation of 
DNA-damage response pathways. Therefore, a treatment combining irradiation and an anti-
PD-1 immune checkpoint blockage (ICB) effectively provoke cancer cell eradication by 
alleviating multiple immunosuppressive mechanisms present in numerous types of cancer, for 
instance in head and neck squamous cell carcinoma (HNSCC). In this study, we investigated 
the expression of PD-L1 after X-ray and proton irradiation at several doses and timings after 
irradiation, in order to determine in which condition an anti-PD-1 ICB in combination with X-
ray irradiation would lead to an optimal treatment response. Based on these in vitro results, a 
syngenic in vivo mouse model of HNSCC was set up to assess TAM repolarization and its 
impact on CD8+ TIL activation and exhaustion. We discovered that unlike proton irradiation, 
X-ray irradiation induced a dose- and time dependent increase in PD-L1 expression, both at 
mRNA and protein levels. Additionally, although the combination of an anti-PD-1 ICB with 
X-ray irradiation increased tumor infiltration by immune cells and favors CD8+ TILs response 
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Dans de nombreux types de cancer y compris les cancers tête et cou, l’expression de 
Programmed death ligand-1 (PD-L1) par les cellules cancéreuses leur permet de survivre et 
proliférer étant donné que cette protéine leur permet d’échapper au système immunitaire.  
PD-L1 se lie à son récepteur à la surface des lymphocytes T cytotoxiques infiltrant la tumeur 
(CD8+ TILs) et induit une voie de signalisation inhibitrice interférant avec l’activation des 
lymphocytes T suite à la reconnaissance d’un antigène spécifique via le T cell receptor. Le 
blocage des voies inhibitrices en empêchant l’interaction entre le ligand et son récepteur, une 
stratégie qui a mené au prix Nobel de médecine et physiologie en 2018, est un nouvel outil 
puissant en immunothérapie et est fréquemment associé aux traitements conventionnels. Outre 
l’expression de PD-L1, les cellules cancéreuses sont capables de polariser les macrophages 
associés aux tumeurs (TAMs) vers un phénotype M2-like favorisant plusieurs mécanismes 
immunosuppresseurs au niveau du microenvironnement tumoral et induisant l’inactivation ou 
même l’apoptose des lymphocytes infiltrant la tumeur. Il a été démontré qu’une irradiation peut 
repolariser les macrophages d’un phénotype M2 vers un phénotype immunostimulant M1-like. 
En plus, une irradiation par rayons X induit la surexpression de PD-L1 dans les cellules 
cancéreuses en activant les voies de réponse aux dommages à l’ADN. Un traitement combiné 
d’irradiation par rayons X et un blocage du checkpoint immunitaire (ICB) anti-PD-1 peut donc 
provoquer l’éradication efficiente des cellules cancéreuses en diminuant les propriétés 
immunosuppressives de nombreuses cellules cancéreuses, par exemple dans le cancer 
épidermoïde de la tête et du cou (HNSCC). Dans la présente étude, nous avons investigué 
l’expression de PD-L1 suite à l’irradiation par rayons X ou par protons à différentes doses et 
timings afin de déterminer dans quelle condition un ICB anti-PD-1 en combinaison avec 
l’irradiation par rayons X pourrait induire une réponse au traitement optimale. Sur base des 
résultats in vitro, in vivo un modèle murin syngénique d’HNSCC a été mis au point pour évaluer 
la repolarisation des TAMs et son impact sur l’activation et l’exhaustion des TILs CD8+. Nous 
avons découvert que contrairement à une irradiation par protons, les rayons X induisent une 
surexpression de PD-L1 dépendante de la dose et du timing au niveau ARN ainsi qu’un niveau 
protéique. En plus, malgré que la combinaison d’un ICB anti-PD-1 et d’une irradiation par 
rayons X augmente l’infiltration tumorale par les cellules immunitaire et la réponse des TILS 
CD8+ envers les cellules cancéreuses, ce processus semble être indépendant d’une 
repolarisation des TAMs par irradiation. 
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 With an estimated number of 9.6 million deaths in 2018, cancer is a significant global 
health threat and the second cause of death worldwide, following cardio-vascular diseases. 
Since its first description by Hippocrates, the so-called Father of Medicine, tremendous efforts 
have been made, trying to understand the nature of cancer and how to cure it. Nowadays, cancer 
is commonly considered as an adaptive genetic disease, which originates from the malignant 
transformation of one of our own cells consecutive to the accumulation of genomic alterations, 
including mutations and epigenetic modifications.  
 
 Cancer cells can be characterized by ten hallmarks, as descripted by D. Hanahan and R. 
Weinberg. According to this definition, cancer cells present sustained proliferative signaling, 
growth suppressor evasion, enabled replicative immortality, active invasion and formation of 
metastasis, genome instability and mutations, resistance to cell death, dysregulated cellular 
metabolism, induction of angiogenesis, evasion of immune destruction and stimulation of 
tumor-promoting inflammation (Hanahan and Weinberg, 2000 and Hanahan and Weinberg, 
2011).  
 
 During the lifespan of a person, random or stress-induced mutations arise in cells and 
cumulate over the years. Since life expectancy is constantly increasing, the number of 
accumulated mutations also increases. This partially explains the increasing incidence of 
cancer. Additionally, during the last decades and centuries, the average lifestyle changed. 
Nowadays, many people are smokers, consume high quantities of alcohol on a regular basis, do 
not pay attention to an equilibrated nutrition and are more and more sedentary. All of these 
factors are well known risk factors for the development of cancer. While some of them are 
directly mutagenic, others favor cell proliferation. This explains why combining the exposure 
to risk factors like alcoholism and smoking promotes, in combination, synergistically cancer 
development, especially cancers of the head and neck region and the gastro-intestinal tract. 
People’s lifestyle as well as their socio-economic status but also ethnics therefore significantly 
impact the individual risk to develop cancer.   
 
 We currently possess a large arsenal of cancer therapies, including surgery, 
chemotherapy, radiotherapy, targeted therapies and immunotherapies. While the number of 
anti-cancer treatments continuously increases, the number of cancer-associated deaths also 
increases. This is partly due to the resistance of several cancers to therapy. Therefore, in 
addition to inventing new cancer therapies, existing cancer therapies are further investigated, 
so that better understanding of the underlying mechanisms can lead to improve these therapies 
and allow to treat patients more efficiently and to treat those that were non-responsive or 
developed resistance to the treatment previously.  
 
 In this context, this project aimed to investigate the combination of radiotherapy, one of 
the oldest anti-cancer therapies, and immune-checkpoint blockage (ICB), a new addition to 
conventional treatment strategies. One of the advantages is that this combination can be 
applicable to a large number of cancer types and that it became, thanks to recent advances in 
the field of radiotherapy and diagnostic techniques, highly precise and induces unlike 




altering the immune response to cancer cells, a closer investigation of the combined treatment 
of radiotherapy and ICB could allow to improve the way this treatment is used and to make it 

























Figure 1. Regions of origin of head and neck cancer. (adapted from: National Cancer Institute, 2016) 
 
 
Figure 2. Lymph node (LN) compartments of the head and neck region. Submental (Ia) and submandibular LNs (Ib) forming 
the level I LNs. The level 2 upper jugulary LNs are subdevinded anterio-media (IIa)l and posterior-lateral (IIb) LNs. Level 3 
and 4 LNs are middle jugular (III) and lower jugular (IV) LNs respectively. Level V LNs consist of the accessory nodes (Va) 
and transverse cervical and supraclavicular nodes (Vb). Pretrachial, paratracheal, precricoid and perithyroid LNs form level 
VI LNs, while suprasternal LN form level VII nodes. (adapted from: http://www.endocrinesurgery.net.au/lymph-node-
management) 
www.unamur.be







1 Head and neck cancer  
 
1.1 Characteristics  
 
Head and neck cancer (HNC) is the sixth leading cancer worldwide, with an incidence of 
approximately 600 000 new cases each year. It is characterized by a 5-year survival of 40-50% 
(Jemal et al., 2011; Leemans et al., 2011; Siegel et al., 2017). It may arise in different segments 
of the upper aero-digestive tract, including the larynx, pharynx, tongue, oral and nasal cavity 
as well as the paranasal sinuses (Figure 1). These parts of the body are particularly sensitive to 
the induction of carcinogenesis, since they are the first line barriers between the body and 
ingested or inhaled substances.  
 
 The lymphatic drainage of all of these regions occurs through several lymph nodes (LN) 
of the neck and upper mediastinum. These LNs are located in seven compartments (Figure 2). 
Precise determination of the individual lymphatic drainage of each HNC patient has shown to 
be crucial, not only for surgical resection but also to set up the optimal irradiation protocols of 
head and neck tumors (Grégoire et al., 2014). According to their possible locations, the side 
effects of tumor growth and treatment protocols can lead to sever discomfort and impairment 
or even loss of several functions including swallowing, speaking, breathing and production of 
saliva. The determination of the precise lymph drainage of head and neck tumors not only 
allows a decreased probability of relapse but it also significantly reduces the irradiation of 
healthy tissues and thereby significantly lowers the side effects HNC treatment (Daisne et al., 
2015). 
 
Considering the anatomic and histologic differences of the potential tissues of origin, there 
is a broad range of head and neck squamous cell carcinomas (HNSCC), adenocarcinomas and 
sarcomas. In this project, we exclusively focused on the most frequent type of HNC, the 
HNSCC. 
 
Following precancerous lesions including leuko- and erythroplakia, smoking and alcohol 
consumption represent the two leading risk factors, which act in combination synergistically. 
While smoking directly induces mutagenesis, alcohol consumption irritates the aero-digestive 
tract killing epithelial cells of the mucosae and thereby stimulation stem cell proliferation. 
Combined smoking and alcohol consumption therefore favors clonal expansion of potentially 
mutated cells, which greatly increases the risk to develop a HNSCC. Epidemiologic studies 
indicate a decreased incidence in western countries, an increased incidence in males with 
African descendants but also in countries with lower socio-economic status, which can be 
explained by a higher exposure to risk factors (Kim et al., 2010). In addition, oropharynx 
infections by some strains of human papilloma virus (HPV) have in recent years been associated 
to a significantly increased prevalence of HNSCC but also to a better prognosis (Gregoire et 
al., 2010). The mechanisms of pathogenesis in HPV+ and HPV- HNC are different. Therefore, 
studies analyzing fundamental processes of HNC should clearly distinguish these two types of 














Figure 5. 5-Fluorouracil (5-FU) is converted to three main active metabolites: fluorodeoxyuridine monophosphate (FdUMP), 
fluorodeoxyuridine triphosphate (FdUTP) and fluorouridine triphosphate (FUTP). 5- Fluorouracil (5-FU) can activate p53 
by more than one mechanism: incorporation of fluorouridine triphosphate (FUTP) into RNA, incorporation of 
fluorodeoxyuridine triphosphate (FdUTP) into DNA and inhibition of thymidylate synthase (TS) by fluorodeoxyuridine 
monophosphate (FdUMP) with resulting DNA damage. (adapted from: Longly et al., 2003) 
Introduction	
	 5	
1.2 Classification  
 
The TNM classification allows to categorize the extent of a patient’s cancer based on three 
criteria: “T” the primary tumor size; “N” the regional lymph node involvement; “M” the 
presence of distant metastasis (Figure 3). It is specific to each type of cancer, depending on the 
tissue of origin. This classification of an otherwise infinitely complex and diverse disease 
allows to guide the choice of treatment and to provide indications regarding the prognosis and 
treatment responsiveness.  
 
 
1.3 Treatment strategy 
 
It is important to note that no official guidelines clearly exist ruling on which therapy to use 
in each case. However, depending on the TNM stage, current treatment for patients with 
HNSCC generally consists in surgical excision and/or radiotherapy, possibly combined with 
chemotherapy in cases of locally advanced tumors, formation of metastasis and tumor 
recurrence. However, chemo- and radio-resistances remain widely unpredictable and are the 
primary cause of poor patient outcomes (Vermorken and Specenier, 2010).  
 
1.3.1 Chemotherapy  
 
Chemotherapy is used as cytotoxic and radio-sensitizing agent in cases of locally advanced 
or metastatic cases of HNSCC if the patient’s condition allows chemotherapy treatment. It is 
most often platinum-based, when combined with radiotherapy or 5-fluoro-uracyl (5-FU) and 





Platinum-based chemotherapy such as carboplatin or cisplatine, which is one of the oldest 
anti-cancer drugs, binds covalently via alkyl groups to purine bases of DNA forming cross-
links or DNA-adducts (Figure 4). These cross-links inhibit cell cycle progression in the G1 or 
S phase and induce cell cycle arrest, which can either be resolved by DNA repair or by the 
induction of apoptosis via the intrinsic pathway. Additionally, cisplatin induces or increases 
oxidative stress which damages intracellular molecules. This process further leads to cell 




5-FU is an anti-metabolite, whose active forms fluorodeoxyuridine monophosphate 
(FdUMP), fluorodeoxyuridine triphosphate (FdUTP) and fluorouridine triphosphate (FUTP) 




damage after entering the cell. These processes lead to cell cycle arrest through p53 activation 




In some cases, paclitaxel is used in addition to platin-based chemotherapy. Paclitaxel 
stabilizes the polymerized form of microtubules assembled during the M phase of the cell cycle 
and prevents microtubule depolymerization. After microtubules attached the kinetochores at 
the centromere region of chromosomes, microtubule depolarization is required not only to 
separate sister chromatids but also to create tension in both chromatids, which inactivates the 
tension sensor Aurora B Kinase and stabilizes the bipolar binding of sister chromatids. If no 
tension is generated at the kinetochore, Mad2 inhibits the Cdc20-APC complex that is 
responsible for M-Cdk and securin degradation necessary for cell cycle progression at the 
APC/C checkpoint. Thereby, Paclitaxel blocks mitosis and prolongs APC/C checkpoint 




Radiotherapy is one of the most frequently used strategies for treating HNC at different 
stages. Due to the high precision of modern radiotherapy coupled with functional and 
topological medical imaging, in case of early stage HNC, radiotherapy can even replace surgery 
and serve as primary treatment for unresected tumors. Considering the high risk of occult nodal 
metastasis, preventive nodal irradiation is often mandatory for locally restricted tumors. In 
cases of LN infiltration, imaging is used to determine specific lymph drainage of the tumor and 
to define subsequently the area that will undergo radiotherapy alone or post-surgically. In these 
cases, post-operative chemo-radiation is recommended. In clinics, fractioned irradiation is used 
for patient treatment. The total radiation dose is generally 70 Gy, delivered in daily 2 Gy 




Similarly to radiotherapy, in early stages, surgery often allows complete resection of local 
tumors. In case of LN infiltration or some cases of in situ carcinoma, additional post-operative 
radiation can be needed to obtain clear resection margins.  
  
1.3.4 Cetuximab  
 
Epidermal growth factor receptor blockage is nowadays a commonly used targeted therapy 
for HNSCC. This can be achieved using Cetuximab, a humanized anti-EGFR antibody. It is 
used in combination with radiotherapy in cases of locally advanced stages, when patients can 
not sustain chemotherapy. Patients with metastatic HNSCC are treated with the combination of 








Figure 6. Summary of the CTLA-4 and PD-1 immune checkpoints and the role of FDA-approved immune checkpoint inhibitors 
in the treatment of cancer. CD80/CD86 co-stimulation through CD28 provides important activating signals that promote T 
cell expansion and effector differentiation during the induction phase of an immune response. The CTLA-4 co-inhibitory 
receptor is expressed on recently activated T cells and binds to the same ligands as CD28 but with higher affinity. Engagement 
of CTLA-4 on T cells during the induction phase of an anti-tumor immune response therefore impedes T cell activation by 1) 
sequestering CD80/CD86 ligands that would otherwise signal through CD28 and 2) transmitting inhibitory signals that 
directly suppress T cell activation, both of which lead to the induction of anergy. Anti-tumor T cells that do acquire cytokine-
secreting and cytolytic effector functions can undergo additional negative regulation during encounter with tumor cells or 
tumor-associated APC that express PD-L1 in the tumor microenvironment. Engagement of PD-1 on these T cells transmits 
signals that promote T cell exhaustion. Immune checkpoint inhibitors (highlighted in red text) targeting CTLA-4, PD-1, or PD-
L1 block these mediators of negative regulation in T cells, thereby promoting anti-tumor T cell activation and maintenance of 








Figure 7. Additional cytotoxic mechanisms induced by IgG1 anti-PD-L1 antibodies. Anti-PD-L1 IgG1 antibodies bind to 
PD-L1 at the surface of cancer cells and induce, in addition to block receptor-ligand interaction, cancer cell death by NK cell 
mediated antibody-dependent cellular cytotoxicity, opsonisation followed by phagocytosis as well as complement-mediated 
cytotoxicity and cell lysis by membrane attack complex (MAC) formation. (adapted from: Weiner, 2015) 
 
Fig. 1. Summary of the CTLA-4 and PD-1 i mune checkpoints and the role of FDA-approved immune checkpoint inhibitors in the treatment of cancer. CD80/CD86 co-stimulation through CD28 provides important
activating signals that promote T cell expansion and effector differentiation during the induction phase of an immune response. The CTLA-4 co-inhibitory receptor is expressed on recently activated T cells and binds to the
same ligands as CD28 but with higher affinity. Engagement of CTLA-4 on T cells during the induction phase of an anti-tumor immune response therefore impedes T cell activation by 1) sequestering CD80/CD86 ligands
that would otherwise signal through CD28 and 2) transmitting inhibitory signals that directly suppress T cell activation, both of which lead to the induction of anergy. Anti-tumor T cells that do acquire cytokine-secreting
and cytolytic effector functions can undergo additional negativ regulation during encounter with tumor cells or tumor-associated APC that express PD-L1 in the tumor microenviro ment. Engagement of PD-1 on these T
cells transmits signals that promote T cell exhaustion. Immune checkpoint inhibitors (highlighted in red text) targeting CTLA-4, PD-1, or PD-L1 block these mediators of negative regulation in T cells, thereby promoting










1.3.5 Immune-checkpoint blockade 
 
In recent year, advances in immunotherapy provided an additional strategy for HNC 
treatment. For instance, inhibiting negative immune-checkpoints between cancer cells and 
immune cells, which will be detailed more extensively in the third part of the introduction, 
became one of the most famous and efficient additions in cancer therapy. This strategy is 
particularly interesting since it is applicable to a large proportion of cancer patients and presents 
only very faint adverse effects compared to conventional treatments, when used to treat locally 
advanced or metastatic cancer. This new strategy was rewarded in 2018 the Nobel Prize in 
Physiology and Medicine. Indeed, J. Allison and T. Honjo discovered the two negative immune 
checkpoints, that are nowadays targeted in cancer therapy, cytotoxic T-lymphocyte-associated 
protein 4 (CTLA-4) and PD-1. 
 
1.3.5.1 CTLA4 / CD80/86 checkpoint inhibition 
 
Upon T cell activation by antigens and co-stimulation through the interaction of CD28 and 
CD80 or CD86, T cells express the inhibitory signaling receptor CTLA-4, which also binds 
CD80 and CD86 but which higher affinity and avidity than CD28, allowing to induce T cell 
anergy following activation (Figure 6). Blocking this negative pathway was the first FDA 
approved ICB in 2011. That for, the monoclonal antibody Ipilimumab binds to CTLA-4 and 
prevents its interaction with CD80 and CD86, favoring prolonged T cell activation (Hargadon 
et al., 2018).  
 
1.3.5.2 PD-1 checkpoint inhibition 
 
The PD-1/PD-L1 axis is a negative regulator of T cells contributing to immune-
homeostasis and allowing T cell inactivation after their stimulation by an antigen (Figure 6). 
This negative regulator allows to avoid excessive immune activation or auto-immune reactions. 
Cancer cells can exploit this pathway to escape T cells. Blockage of the PD-1 receptor prevents 
receptor ligand interaction and allows to maintain the effector phase of anti-tumor T cell 
response. In 2014, the Food and Drug Administration (FDA) approved two anti-PD-1 IgG4 
antibodies, Nivolumab and Pembrolizumab.  
 
1.3.5.3 PD-L1 checkpoint inhibition 
 
Similarly to PD-1 checkpoint inhibition, anti-PD-L1 antibodies prevent receptor ligand 
interaction and allow to maintain the effector phase of anti-tumor T cell response. However, 
the target of these antibodies is not located on immune cells but cancer cells. During the 
development of anti-PD-L1 monoclonal antibodies, IgG1 antibodies were selected. The Fc 
fraction of G1 immunoglobulins, generates two additional secondary cytotoxic mechanisms, 
which favor cancer cell destruction by the immune system (Figure 7). First, the Fc fraction of 
IgG1 antibodies can bind to FcγR receptors I, II-A, II-B1, II-B2 and RIII, present at the surface 
of different immune cells, for instance macrophages, natural killer (NK) cells and granulocytes. 




phenotype, FcγRIII activation on NK cell induces antibody dependent cytotoxicity, which will 
induce cancer cell lysis similarly to cytotoxic T cells (Bournazos et al., 2016). This mechanism 
will be described in section 3.1.2.1. The second additional mechanism of cytotoxicity is 
mediated by the activation of the complement, which is part of the innate immune system. The 
C1 complex binds to the Fc fraction of the IgG1 antibodies via the C1q subunit inducing a 
conformational change of the C1 complex. This leads to the activation of the auto-catalytic 
activity of the C1r subunit inducing the cleavage of the activated C1s subunit, which is a serine 
protease. This protease cleaves C2 into C2a and C2b but it also cleaves C4 into C4b, which 
binds covalently to the surface of the cancer cell. C2a associates to C4b, forming the active 
convertase C3, which cleaves C3 into C3a and C3b. C3b remains bound to the surface of cancer 
cells, while C3a is released and acts as a mediator of inflammation. Since C3b opsonizes cancer 
cells and thereby favors their phagocytosis of the target cells. C3b also binds to the C3 complex, 
which then, in its active form, can cleave C5 into C5a and C5b. Similarly to C3a, C5a favors 
inflammation. It also binds to the C5a receptor at the surface of macrophages, which than can 
bind C3a by the CR1 receptor and phagocyte opsonized target cells. C5b binds to C6, C7, C8 
and C9 forming the membrane attack complex, which disrupts target cell membranes and 
causes cancer cell lysis (Murphy and Weaver, 2017).   
 
In 2016, the first PD-L1 blocking antibody was approved, Atezolizumab, followed in 2017 
by two other PD-L1 blocking antibodies, Avelumab and Durvalumab (Hargadon et al., 2018).  
 
Current investigations aim to determine how the unique features of each of the available 


















Figure 9. Depth dose profile of charged particles and photons. (adapted from: Ladra and Yock., 2014) 
 
 
from water radiolysis (indirect effects of ionization), affect-
ing an estimated 2000 primary ionization events (351). The
timing attributes of cellular damage inflicted by IR range
from chemical reactions occurring as rapidly as 0.01 ps after
IR to major cellular effects that occur in the range of minutes
to hours (308). Direct radiation damage is initiated in the
range of 10 - 14–10 - 12 s with the breaking of S–H, O–H,
N–H, and C–H bonds. Widespread biomolecular damage
induced by radiolytic products of water begins within 1 ps
(10 - 12 s), along with thiol depletion and further bond
breaking (e.g., C–C and C–N). By 1 ms after IR exposure, the
reactions of nascent !OH, H!, and eaq
- are mostly completed
and DNA repair processes are initiated. Though the activity
of some reactive IR products has diminished, an important
event occurring through *10 s post-irradiation is the in-
creased intracellular formation of ROS and RNS species
through mechanisms described next (section ‘‘Endogenous
propagation of IR-induced ROS’’). The cumulative effects of
the early, rapid biochemical processes are manifested in later
stages of cellular damage, including the slowing of mitosis,
damage to protein signaling networks, and membrane rupture,
estimated to occur over the course of minutes to 10 h (308).
Endogenous propagation of IR-induced ROS
The overall amount of ROS generated from primary ion-
ization events is further propagated via the intracellular ac-
tivation of endogenous ROS-producing systems such as
nicotinamide adenine dinucleotide phosphate, reduced form
(NADPH) oxidase, and the mitochondrial electron transport
chain (ETC) (12, 191, 235, 247, 351). IR exposure has been
definitively linked to mitochondria-dependent ROS/RNS
generation in tumor cells (95). Increased ROS generation in
mitochondria after low-dose IR significantly contributed to
radiosensitivity and cell survival (10). Whole body irradia-
tion of rats resulted in the increased activity of cytochrome
oxidase and NADH-cytochrome c reductase, decreased an-
tioxidant activity, and increased lipid peroxidation in live
mitochondrial fractions (170). Irradiation of A549 cells in-
duced mitochondrial ROS production, increased mitochon-
drial membrane potential, and promoted respiration and ATP
production (367). Similarly, an increased expression of
NADPH oxidase was reported after irradiation with 10 Gy in
rat brain microvascular endothelial cells, and the inhibition of
NADPH oxidase led to a decrease in IR-generated ROS (79).
IR-induced chromosomal instability in hematopoietic stem
cells (6.5 Gy) was reversed by NADPH oxidase inhibition
using diphenylene iodonium (262). The mechanisms of
NADPH oxidase activation by IR may involve ceramide
signaling, which is discussed later in this review. In addition
to NADPH oxidase activation, a 2.5 Gy dosage of IR was
shown to induce mitochondrial ROS production that can be
blocked by inhibitors of mitochondrial respiration (66).
The temporal propagation of IR effects is also achieved
through nitrosative stress mechanisms. A study of murine bone
marrow stromal cells showed that irradiation with 2–50 Gy
stimulated the expression of nitric oxide synthase (inducible
nitric oxide synthase [iNOS]), leading to a dose-dependent
increase in !NO levels in vitro along with the increased oc-
currence of nitrated tyrosine residues in vivo (128). Significant
increases in the expression of iNOS and elevated levels of
nitrate and nitrite have been associated with radiation-induced
epithelial dysfunction in the colon (112). In addition to directly
modifying tyrosines, cysteines, and hemes, !NO is the en-
dogenous precursor to ONOO- and other RNS (23). The ac-
tivation of ROS- and RNS-producing pathways by IR is
particularly important, as it illustrates a targeted localized
increase in these reactive species as a consequence of global
IR-induced ROS production, selectively altering cellular sig-
naling and a host of metabolic pathways.
The complex chemical interplay of ROS/RNS generated
directly by IR and through derivative systems such as
NADPH oxidase, iNOS, and mitochondrial ETC is summa-
rized in Figure 1. O2
! - , H2O2,
!OH, and ONOO- are espe-
cially reactive, damage a wide range of cellular biomolecules,
and react with each other to generate additional ROS/RNS. For
example, the powerful oxidant peroxynitrite decays rapidly in
acidic conditions (pKa 6.8) and forms the highly potent sec-
ondary oxidant NO2
! (22, 40). In general, the relatively milder
oxidants (e.g., H2O2) target biomolecules in a more selective
manner, while ROS with higher reactivity, such as !OH, are
promiscuous; selected chemical examples appear throughout
the next few sections.
Detection of intracellular ROS and RNS is routinely
achieved using targeted probes, including fluorescent redox
dyes such as dichlorodihydrofluorescein (DCF assay) and
chemiluminescent methods (e.g., for !NO detection) (138,
352). Numerous caveats are associated with these methods,
particularly with regard to cross-reactivity, and, thus, the
development of more selective methods, such as the
FIG. 1. IR generates the potent intracellular oxidants
H2O2, O2
!2, and !OH, along with reductants H! and eaq
2.
Endogenous ROS propagation occurs through the mitochon-
drial ETC and the increased expression of signaling enzymes
such as NOX and iNOS. Reductive stress induced by IR leads
to loss of sulfur in protein methionine and cysteine residues.
!OH, hydroxyl radical; O2
! - , superoxide; eaq
- , hydrated
electron; H!, hydrogen radical; H2O2, hydrogen peroxide;
iNOS, inducible nitric oxide synthase; IR, ionizing radiation;
NOX, NADPH oxidase; ROS, reactive oxygen species. To see
this illustration in color, the reader is referred to the web
version of this article at www.liebertpub.com/ars




photons,! the! maximal! dose! is! delivered! within! few! centimeters.! The! dose! decreases! when!
photons! get! through! the!matter,! thus! irradiating!normal! tissue!upstream! (entrance!dose)! and!
downstream!(exit!dose)!the!tumor.!Protons!travel!through!the!matter!with!minimal!interactions!
until!they!reach!a!given!depth,!where!the!energy!is!deposited.!This!highEdose!region!is!called!the!
Bragg! Peak.! As! the! width! of! the! Bragg! Peak! is! not! large! enough! to! cover! the! entire! targeted!


















2 Radiotherapy  
 
Since the discovery of X-rays by Wilhelm Röntgen in 1895 and their first applications in 
cancer treatment at the end of the 19th century, considerable advances have been made in the 
use of ionizing radiation (IR) for cancer patient treatment (Bernier et al., 2004). These advances 
allowed to maximize the efficiency of radiotherapy while lowering its adverse effects. 
Additionally, charged particle therapy has emerged as an alternative to X-ray or γ-ray 
irradiation, further improving radiotherapy efficiency. Even nowadays, radiotherapy remains 
one of the most frequently used treatment strategies because of its high cytotoxic effects on 
cancer cells as well as its immunogenic properties.  
 
 
2.1 Physical aspects of radiotherapy 
 
During the interaction between ionizing radiation and the electrons of target molecules, the 
energy deposition of photons and charged particles leads to the ejection of electrons from their 
orbitals and induces the ionization of target atoms and molecules. This way, highly reactive 
chemical compounds are formed, including reactive oxygen species (ROS). ROS cause the 
ionization of other molecules, including lipids, proteins and DNA leading to a catastrophic 
disruptions of normal cell functions such as metabolism and DNA replication (Figure 8) (Reisz 
et al., 2014). Additionally, DNA can be directly damaged by ionizing radiation. These 
physicochemical reactions induced by the interaction between radiation and matter eventually 
lead to the primary biological effects of radiotherapy. 
 
 
2.2 Photon irradiation  
 
Conventional radiotherapy uses energy in form of electromagnetic waves (X-ray or γ-ray) 
to destroy cancer cells. Unlike charged particles, when photons enter into matter, the energy 
deposition undergoes an initial increase, consistent with the maximal dose of radiation. From 
then on, the dose of radiation progressively decreases throughout the passage through the matter 
(Figure 9). As a result, when tumors are treated by conventional radiotherapy, the healthy tissue 
upstream of the tumor, on the radiation trajectory, absorbs relatively high doses of radiation 
compared to the tissue downstream the tumor on the same trajectory. Even though precise 
mapping of the lymphatic drainage as well as technical advances like three-dimensional 
conformal radiation therapy (3D-CRT) and intensity-modulated radiation therapy (IMRT), 
decrease the radiation dose absorbed by healthy tissue, further improvements remain to be made 















Figure 11. DNA damage induced by low LET and high LET radiation and associated repair mechanisms. (adapted from: 
Mohammed et al., 2017) 
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Figure 3. Repair of high- and low-LET radiation-induced DNA damage. Low-LET radiation-induced 
DNA double-strand breaks (DSBs) are typically repaired by non-homologous end joining (NHEJ) or 
both NHEJ and homologous recombination (HR) if cells are in S or G2 phases of the cell cycle. The 
repair of complex DSBs generated by high LET radiation including carbon ions is poorly understood. 
The less efficient repair response after high-LET radiation leads to DNA damage remaining 
unrepaired for long periods of time and eventually may promote genome instability and cell death. 
It is evident that the high RBE of charged particle radiation is due to the abundance of irreparable 
breaks induced in the cells as compared to low LET radiation [33,54]. However, how these irreparable 
breaks translate to high cell lethality is not well understood. Heavy ion radiation has been shown to 
down-regulate pro-survival protein kinase B (AKT) signaling, which leads to activation of pro-death 
signaling mechanisms such as autophagy and apoptosis [55]. Another potential mechanism for DNA 
damage response to carbon ion radiotherapy (CIRT) is mitotic catastrophe. In a study of 20 different 
human cancer cell lines exposed to cisplatin, PhXRT and/or C-ions, apoptosis and senescence were 
common to all treatments but mitotic catastrophe was differentially triggered by CIRT [56]. The 
authors argued that the less efficient repair of the more complex DSBs after CIRT leads to aberrant 
mitosis and subsequent mitotic catastrophe. Similar dependence on mitotic catastrophe was reported 
in other studies utilizing the radio-resistant HNSCC cell line SQ20B with emphasis on a sub-
population of CIRT resistant cells, likely cancer stem-like cells, which are able to escape this death 
mechanism and renter the cell cycle due to increased self-renewal potential and reduced apoptotic 
machinery [57,58]. Clustered DNA damage with dense IRIF along the particle track can dramatically 
increase the probability of chromosomal aberrations compared to X-rays in human lymphocytes [59] 
and their hematopoietic progenitors [60]. Extreme proximity of DSBs in clustered lesions may also 
give rise to increased chromosomal rearrangements [61] which was in agreement with computational 
modeling data [62]. Utilizing cytogenetic techniques like G2 premature chromosome condensation 
(G2 PCC) and multicolor banding fluorescence in situ hybridization (mFISH), it has been shown that 
charged particle radiation is more effective at inducing chromosomal aberrations when compared to 
low LET radiation [63–66]. Cells harboring unrepaired breaks that move through the cell cycle 
uninhibited due to lack of proper G2 checkpoint activation propagate chromosomal aberrations or 
undergo mitotic catastrophe [22]. Many other groups investigated the uniqueness of DNA damage 
and DNA damage response after heavy particle irradiation. The impact of telomere length [67] and 
glutathione metabolism/depletion [68], for example, were proposed as potential players in the 
differential response to particle radiation in contrast to PhXRT. 
4. Preclinical Research in Carbon Ion Radiotherapy 
Given the aforementioned physical, biophysical and biological characteristics of C-ion beams, 
carbon ion radiotherapy (CIRT) has the potential to improve local control and reduce normal tissue 
complications in treating cancer patients especially those with deep-seated and traditionally radio-
Figure 3. epair of high- and lo -LET radiation-induced DNA damage. Lo -LET radiation-induced
double-strand breaks ( SBs) are typically repaired by non-ho ologous end joining ( EJ) or
both NHEJ and homologous recombination (HR) if cells are in S or G2 phases of the cell cycle. The repair
of complex DSBs generated by high LET radiation including carbon ions is poorly understood. The less
efficient repair response after high-LET radiation leads to DNA damage remaining unrepaired for long
periods of time and eventually may promote genome instability and cell death.
It is i ent t at t e i f c r e rticle r iation is e t t ce f irre arable
breaks induced in the cells as c ared to l r iation [ , 4]. r, t ese irre arable
breaks translate to high cell lethality is not ell understood. eavy ion radiation has been sho n to
do n-regulate pro-survival protein kinase B (AKT) signaling, hich leads to activation of pro-death
signaling echanis s such as autophagy and apoptosis [55]. t er te tial ec anis for
da age response to carbon ion radiotherapy ( IRT) is itotic catastrophe. In a stu y of 20 different
hu an cancer cell lines exposed to cisplatin, PhXRT and/ r -io s, apo tosis and senescence ere
co on to all treatments but mitotic catastrophe was differentially triggered by CIRT [56]. The authors
argued that the less efficient repair of the m re co plex DSBs after CIRT leads to aberrant mitosis
and subsequent mitotic catastrophe. Similar dependence o mitotic catastrophe was reported in ther
studies utilizing the radio-resistant HNSCC cell line SQ20B with emphasis on a sub-population of CIRT
resistant cells, likely cancer stem-like cells, which are able to escape this death mechanism and renter the
cell cycle due to increased self-renewal potential and reduced apoptotic machinery [57,58]. Clustered
DNA damage with dense IRIF along the particle track can dramatically increase the probability of
chromosomal aberrations compared to X-rays in human lymph cytes [59] and their hematopoietic
progenitors [60]. Extreme proximity of DSBs in clustered lesions may also give rise to increased
chromosomal rearrangements [61] which was in agreement with computational modeling data [62].
Utilizing cytogenetic techniques like G2 premature chromosome condensation (G2 PCC) and multicolor
banding fluorescence in situ hybridization (mFISH), it has been shown that charged particle radiation
is more effective at inducing chromosomal aberrations w en compared to low LET radiation [63–66].
Cells harboring unrepaired breaks that move through the cell cycle uninhibited due to lack of proper G2
checkpoint activation propagate chromosomal aberrations or undergo mitotic catastrophe [22]. Many
other groups investigated the unique ess of DNA damage and DNA damage response after heavy
particle irradiation. The impact of telomere length [67] and glutathione metabolism/depletion [68],




2.3 Charged particle irradiation 
 
In case of charged particle irradiation, such as carbon ion or proton irradiation, the 
accelerated particles slow down once they entered the target matter, leading to a small energy 
deposition by the transfer of the particle kinetic energy to the target, called liner energy transfer 
(LET). At a certain point on their trajectory, depending on the initial energy of the particles, 
they rapidly slow down, delivering the majority of their energy at that specific point in space. 
The depth-dose profile distribution of charged particle irradiation, shows, depending on the 
initial particle energy, the depth at which occurs a maximal dose deposition, called the Bragg 
peak (Figure 9). This explains how irradiation of tumors by charged particles leads to very low 
irradiation of healthy tissue upstream the target and almost zero irradiation downstream of the 
target, compared to conventional radiotherapy. The use of proton and carbon ion irradiation 
therefore allows to use much higher radiation doses and a reduction of off-target irradiation 
(Schiller et al., 2016; Chen and Ahmad, 2012). Additionally, it has been shown that the relative 
biological effectiveness of charged particle irradiation, which compares the biological 
effectiveness compared to X-ray irradiation, especially that of carbon ions, reaches 2 or 3, 
further indicating advantages of charged particle irradiation over conventional radiotherapy in 
cancer treatment (Miller et al., 2013). 
 
 
2.4 Chemical and biological effects of radiotherapy 
 
2.4.1 DNA damage  
 
Unlike most molecules inside a cell, there are only few copies of DNA and it is not 
continuously resynthesized, unless a cell undergoes mitosis. In addition, DNA plays a key role 
in most cell functions. Therefore, DNA damage induced directly or indirectly by IR has more 
significant long term consequences than for example the ionization of a lipid or mRNA 
molecule and can eventually lead to cell death (Figure 10). It has been shown that radiation 
LET determines the nature of DNA damage resulting from target irradiation. Indeed, the 
majority of DNA damage induced by photons is the result of indirect damage caused by the 
interaction with ROS, such as hydroxyl radicals and superoxide, produced by water molecule 
radiolysis (Reisz et al., 2014). These reactions mainly result in single strand breaks (SSB) of 
the DNA, which can subsequently give rise to simple double strand breaks (DSB), that present 
a widespread spatial resolution (Khanna, 2015). On the other hand, high LET radiation induces 
more complex clustered DNA double strand breaks (DSB) and this, primarily through direct 
DNA damage (Figure 11) (Lomax et al., 2013). While simple DSB usually are repaired by 
homologous endjoining (HEJ) during the S phase and by non-HEJ (NHEJ) during the G1 and 
S phase of the cell cycle, complex DSB induced by high LET radiation, protons for instance, 
cannot be repaired by NHEJ and are less efficiently repaired by HEJ (Wang et al., 2008; Rostek 
















2.4.2 DNA repair mechanisms 
 
2.4.2.1 Damage response initiation  
 
Once DSB occur, they are recognized by the MRN complex formed of the MRE11, RAD50 
and NBS1 heterohexatrimer, which binds to the damaged site and recruits the kinase ataxia 
telangiectasia mutated (ATM) (William et al., 2010). Upon activation by auto-phosphorylation 
on serine 1981, the kinase ATM phosphorylates histone H2AX at serine 139 (γH2AX) at the 
damaged site. γH2AX is then recognized by MDC1, which will extend the H2AX 
phosphorylation. MDC1 recruits RNF8 and RNF186, which subsequently polyubiquitinylate 
the histone H2A leading to the recruitment of BRCA1 promoting DNA repair by homologous 
recombination (Figure 12). Methylated histones H2A and H2AX as well as 
monoubiquitinylated histones H2A and H2AX by RNF186 are bound by 53BP1, which favors 
DNA repair by NHEJ. p53 and Chk1 can also be recruited by MDC1 and γH2AX. Upon their 
activation by phosphorylation through ATM, these proteins induce cell cycle arrest, but if the 
damage becomes persistent, it can lead to apoptosis (Lee et al., 2016). 
 
2.4.2.2 Non-homologous end joining  
 
In case of NHEJ, the KU70/80 heterodimer binds to DNA at the site of the DSB protecting 
it from enzymatic degradation by DNA exonucleases and activation of the HE repair 
mechanism. KU70/80 recruits DNA PKcs, capable of phosphorylating downstream effectors. 
Depending on the length of the single strand ends at the break point, they can be either trimmed 
by the DNA exonuclease Artemis or filled by DNA polymerase µ or λ in order to obtain 
compatible ends at both sites of the break before being ligated by the XRCC4-Lig4-XLF protein 
complex (Figure 13) (Brandsma and van Gent, 2012; Lee et al., 2016). 
 
2.4.2.3 Homologous end joining  
 
Unlike the error-prone NHEJ, HEJ occurs only during the S and G2 phases of the cell cycle 
since it uses sister chromatids as template to insure a more reliable DNA DSB repair. The MRN 
complex bound to the site of the DSB further binds CtIP, which then recruits Exo1 to process 
the DNA to single strand ends. The RPA complex and hSSB1 bind to the single strand end and 
protect it from degradation until the recruitment of the BRCA2-RDA51 complex. This complex 
initiates the formation of the Holiday junction between the two sister chromatids, which are 
joined together by cohesion proteins, before DNA polymerase δ starts the repair of the damaged 







Figure 14. T cell activating and down-regulating pathways and therapeutics targets. Upon binding CD80 or CD86, CTLA-4 
recruits the phosphatases SHP2 and PP2A via the YVKM motif on its cytoplasmic domain. SHP2 recruitment results in the 
attenuation of TCR signaling by dephosphorylating the CD3ζ chain. PP2A recruitment results in downstream 
dephosphorylation of AKT, further dampening the T-cell activation pathway. PD-1 ligation by PD-L1 or PD-L2 also recruits 




3 Cancer immunology 
 
3.1 Tumor infiltrating lymphocytes 
 
3.1.1 T cell activation 
 
 Within the tumor microenvironment (TME), T cells play an important role in detecting 
and destroying cancer cells by specific tumor antigen recognition. Immunogenic cancer cells 
lead to the maturation of dendritic cells (DCs), antigen processing and presentation to T cells. 
Unlike immature DCs, mature DCs additionally express high levels of costimulatory molecules 
and Major Histocompatibility Complex (MHC) (Kroemer et al., 2013). The presented antigens 
can be recognized by naive T cells through the T-cell receptor (TCR) and MHC recognition by 
CD4/CD8. Following the co-stimulation by the interaction between CD28 and CD80/CD86 
(also called B7-1 and B7-2), lymphocyte activation pathways are engaged, which result in 
clonal expansion of effector T cells (Figure 14). This process, called T cell priming by DCs, 
allows T cells to destroy target cells upon antigen recognition by the TCR and CD4/CD8 
binding to MHC II / MHC I, without the need of co-stimulation. This induces the activation of 
the tyrosine-protein kinases LCK and FYN, which phosphorylate the TCR-bound CD3-ζ chain. 
In addition, LCK phosphorylates the tyrosine-protein kinase ZAP70, which is subsequently 
recruited to the phosphorylated CD3-ζ chain. ZAP70 then phosphorylates LAT associated to 
GRB2, LCP2 and PLCγ1 and thereby activates multiple signaling pathways including MAPK, 
NFAT and CREB, involved in cell proliferation, differentiation, motility and interleukine-2 
(IL-2) transcription. In case of co-stimulation by the interaction of CD80/CD86 and CD28, the 
activated LCK kinase further phosphorylates the intracellular domain of CD28, inducing the 
PI3K-AKT-mTOR and PI3K-PKCθ pathways resulting in NFκB and MKK7 activation, 




3.1.2 T cell effector functions 
 
3.1.2.1 CD8+ T cells 
 
 After antigen recognition, cytotoxic CD8+ T cells are capable of inducing apoptosis of 
target cells through several mechanisms at the immunologic synapse. Similar to NK cells, 
activated cytotoxic CD8+ T cells secrete high amounts of perforin and granzymes B upon 
antigen recognition. These two proteins are then endocytosed by target cells. Endosome 
acidification induces perforation of the endosome by perforin, releasing granzymes B into the 
cytosol. This protease cleaves pro-caspase 3 to caspase 3 and Bid to tBid, inducing apoptosis 
of cancer cells. Activated CD8+ T cells also secrete tumor necrosis factor-α (TNF-α) which 
induces the extrinsic pathway of apoptosis, while interferon-γ (IFN-γ) secretion enhances 
macrophage polarization towards and M1-like phenotype and MHC-I as well as MHC-II 




Figure 15. Costimulatory (green arrows) and coinhibitory (red arrows) ligand–receptor interactions between a T cell and a 




Figure 16. CTLA-4 and PD-1 modulate different aspects of the T-cell response: A, CTLA-4 is upregulated after antigen-specific 
activation of a T cell in lymphatic tissue, leading to decreased effector function (early activation phase). B, The immune 
modulation mediated by the PD-1 pathway ensures protection of tissue from collateral damage during an inflammatory 
response as well as auto-immune reactions. Certain cancer cells express the PD-1 ligands B7-1 (CD80), B7-2 (CD86) or B7-
H1 (PD-L1) allowing them to exploit these regulatory mechanisms and evade a tumor-directed T-cell response. (adapted from: 





protein binds to its receptor at the surface of target cells and induces death receptor-mediated 
apoptosis of cancer cells (Murphy and Weaver, 2016). 
 
3.1.2.2 CD4+ T cells 
 
Activated CD4+ T helper cells produce several immunostimulant cytokines including IFN- γ, 
TNF-ß as well as interleukins 2 and 10, which further favor macrophage activation and 
polarization towards a M1-like phenotype and CD8 + T cell activation, survival and clonal 
expansion. IFN-γ induces increased secretion of IL-12 in macrophages and DCs, which again 
increases IFN-γ production. This positive feedback loop promotes M1 polarization of 
macrophages as well as a Th 1 profile over Th 2 profile (Murphy and Weaver, 2016). 
 
 
3.1.2.3 T cell evasion by cancer cells 
 
3.1.2.3.1 Negative immune checkpoints 
 
 Cancer cells are capable of evading immune elimination by several mechanisms 
including the exploitation of negative immune checkpoints such as PD-1/PD-L1 and CTL-
A4/CD80 or CTL-A4/CD86, which normally contribute to self-tolerance and avoid auto-
immune reactions by interfering with the previously described T cell activation pathways 
(Figure 14; Figure 15). The interaction between PD-1 and CTLA-4 with their respective ligands 
leads to the recruitment and activation of SHP-1 and SHP-2, which decrease TCR signaling 
through the dephosphorylation of the CD3-ζ chain. In addition, these phosphatases inhibit PI3K 
and thereby the lymphocyte activation pathway downstream the TCR. Furthermore, CTL-A4 
induction activates another phosphatase, PP2A, which acts downstream the TCR by inhibiting 
AKT and contributing to the inhibition of the lymphocyte activation (Nirschl and Drake, 2013). 
Considering that many cancer cells express PD-L1 and/or CD80/CD86, allowing them to 
prevent TIL activation and to escape immune elimination, the immunologic synapsis offers an 
interesting target for immune checkpoint blockage (Figure 16) (Gong et al., 2018).  
 
3.1.2.4 Low immunogenicity 
 
 Upon selection by cytotoxic T cells during tumor growth, surviving cancer cells often 
present low level of immunogenicity and thereby avoid T cell priming by DCs, which results 
in immune evasion by the cancer cells. Several cancer therapies, such as platin-based 
chemotherapy, and radiotherapy in case of HNC, induce immunogenic cell death and thereby 
stimulate the immune reaction against cancer cells, in addition to their intrinsic cytotoxic 








Figure 17. Macrophage polarization. Through the binding to their respective receptors, M1 stimuli LPS, TNFα, and IFNγ 
trigger the activation of several transcription factors, which include IRF/STAT family members IRF3, IRF5, STAT1, and 
STAT5, the active NFκ heterodimer p50–p65 and HIF1. miR127, miR 155, and miR223 also regulates M1 polarization. When 
polarized to M1-like phenotype, macrophages produce specific cytokines (TNFα, IL-1β, IL-2, IL-6, IL-12, IL-23, IFNγ), 
chemokines (CXCL10) and other molecules (ROS, NO, iNOS and HLA-DR). The M1 phenotype plays key roles in inflammation, 
immunostimulation and an antibacterial and antitumoral responses. M2 stimuli IL-4, IL-13, IL-10, and TGFβ bind to ILR4α, 
ILR10, or TGFβR to induce a M2-like phenotype in macrophages. These stimuli activate several transcription factors: 
IRF/STAT family members IRF4, STAT 3, and STAT6, the inhibitory NFκB homodimer p50–p50 and HIF2. miR14a also 
influences M2 polarization. When polarized in M2-like phenotype, macrophages produce specific cytokines (IL-10), 
chemokines (CCL5, CCL17, CCL18, CCL22), and other proteins (CD163, CD206, Arg1, MMP-9, Fizz-1, Ym-1, and PD-L1). 
M2 macrophages exert diverse functions, such as tissue repair, matrix remodeling, angiogenesis, immunosuppression, and 




Figure 18. TAM-dependent mechanisms driving tumor progression. TAMs alter immune responses by four main mechanisms: 
1) inhibition of T cell activation; 2) inhibition of T cell viability; 3) promotion of Treg induction and recruitment; 4) 




Figure 19. Radiation induced PD-L1 expression. (adapted from: Harris and Kranz, 2016) 
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3.2 Tumor-associated macrophages 
 
 Within the TME, the most predominant immune cells are tumor-associated 
macrophages (TAMs). The phenotype of TAMs is characterized by a high degree of plasticity 
following a polarization gradient between a M2 and a M1 phenotype (Figure 17). M1 
macrophages are bactericidal, pro-inflammatory and capable of immunostimulation, while M2 
macrophages possess anti-inflammatory, angiogenic and immunosuppressive properties (Genin 
et al., 2015; Genard et al., 2017). Cancer cells are often capable of polarizing TAMs towards 
and M2-like immunosuppressive phenotype, either through the secretion of specific cytokines 
such as IL-4, IL-13, TGF-ß, or by creating hypoxic areas within the tumor. TAMs are recruited 
through the action of chemoattractants such as CCL2, CXCL12, CSF1 and VEGFA (Green et 
al., 2009). They are able to interact with other cell types within the TME either by direct contact 
or via secretion products (Hanahan and Coussens, 2012). Cancer cells benefit from several of 
these interactions since M2-like TAMs are capable of impairing T cell activation (PD-L1/PD-
1, CD80/CTLA-4, CD86/CTLA-4), inducing T cell apoptosis (Fas/FasL, TRAIL/TRAIL-R), 
recruiting and activating T regulatory cells (IL-10, TGF-", CCL2) or depleting lymphocyte 
metabolites (L-arginine) and thereby contributing to immunosuppression (Figure 18) (Ugel et 




4 Radiation-induced immune-modulation 
 
4.1 PD-L1 upregulation 
 
 It has been shown that, in response to IR exposure, cancer cells present an increased 
PD-L1 expression, giving an opportunity of increased immune-checkpoint blockage sensitivity 
(Wu et al., 2016). Recent investigations determined for the first time that this irradiation-
induced upregulation is mediated by the formation of double-strand breaks (DSBs) and 
subsequent ATM-ATR-Chk1 kinase activation (Figure 19) (Sato et al., 2017). Precise targeting 
of the PD-1/PD-L1 checkpoint in combination with optimally dosed and timed radiotherapy 
thereby represents a promising strategy in cancer therapy and turned out to be highly successful 
in some types of cancer (Deng et al., 2014; Bardhan et al., 2016). 
 
4.2 Macrophage polarization  
  
 While cancer cells are capable of polarizing TAMs into a M2-like immunosuppressive 
phenotype, which favors cancer cell survival and the formation of metastasis, repolarizing 
macrophages from a M2-like (pro-tumoral) towards a pro-inflammatory M1-like (anti-tumoral) 
phenotype can be used to lower the immunosuppression in tumors and favor cancer cell 
eradication by the immune system. This repolarization toward a pro-inflammatory M1-like 




repolarize TAMs by chemicals, which is associated to significant side effects, radiotherapy 
possesses the advantage to act locally on the parts of the body where the tumor resides, thereby 
limiting collateral damage. The repolarization of macrophages from a M2-like to a M1-like 
phenotype has been observed at moderate doses by photon irradiation (Genard et al., 2017). 
Considering the ballistic advantages of proton irradiation in comparison to X-ray or $-ray 
irradiation, recent studies investigated the TAM repolarization by protons. It was confirmed 
that, in vitro, proton irradiation is capable of polarizing macrophages towards an M1-like 
phenotype. Furthermore, NF%B signalling was determined as a primary driver during this 
repolarization process (Genard et al., 2018).  
 
4.3 Immunogenic cell death 
 
 Although apoptosis was believed to be immunologically silent and tolerigenic, it has 
been reported that, as a result of cell stress, injury or dying, apoptosis can come along with the 
exposure or release of damage-associated molecular patterns (DAMPs). Several chemo-
therapeutic agents like cisplatin as well as ionizing photon irradiation have been shown to be 
able to induce the exposure of DAMPs including calreticulin and heat shock protein 90 at the 
cell plasma membrane. Other DAMPs can be secreted, ATP and high mobility group protein 
B1 (HMGB1) for instance. Photon irradiation is therefore capable of triggering the exposure 
and secretion of DAMPs by cancer cells which can induce a potent anti-cancer immune reaction 
within the TME (Krysko et al.,2012).  
 
 Even though radiotherapy is one of the oldest cancer therapies, it still remains in 
constant evolution and contributes to the discovery and the improvement of new combined 
cancer therapies. By lowering immunosuppression through TAM repolarization from a M2-like 
towards a M1-like phenotype, triggering immunogenic cell death, directly destroying cancer 
cells in targeted areas and enhancing the efficacy of PD-1/PD-L1 checkpoint blockers, 


























 The overall objective of this project was to determine mechanisms underlying the 
synergic effect of PD-1 ICB and radiotherapy using X-ray irradiation. Since we hypothesized 
that the synergic effect of anti-PD-1 ICB and X-ray irradiation on HNSCC is mediated by 
optimal PD-1 ICB administration depending of PD-L1 expression following irradiation and by 
X-ray-induced TAM repolarization, we focused our attention on the radiation-induced 
induction of PD-L1 expression and the radiation-induced TAM repolarization. 
 
 The first objective of this project was to determine in vitro the effects of X-ray 
irradiation on PD-L1 expression in two human and one murine HNSCC cell lines at different 
radiation doses and at different timings post-irradiation. The expression of PD-L1 was assessed 
at mRNA level by RT-qPCR and at protein level by immune-fluorescence labelling. Flow 
cytometry was then performed to determine the relative PD-L1 induction at cell membrane.  
 
 In order to additionally assess PD-L1 expression in THP-1-derived M1 and M2 
macrophages, successful macrophages polarization needed to be performed. This was evaluated 
by measuring the expression of several polarization markers by RT-qPCR. Then PD-L1 
expression was also assessed by RT-qPCR at different doses of X-ray irradiation and at 
different timings post-irradiation.  
 
 Considering the advantages of new radiotherapy techniques such as proton therapy, we 
also started the study of the immuno-modulatory effects of proton irradiation by assessing PD-
L1 expression at mRNA level in one HNSCC cell line at several timings post-irradiation of 
proton irradiation by different doses.  
 
 To investigate the efficiency and the underlying mechanisms of the combined treatment 
of anti-PD-1 ICB and X-ray irradiation in a model of HNSCC, we had to set up a syngenic 
mouse model of HNSCC, that allows the assessment of treatment efficiency. Treatment 
efficacy was defined by the increase in activation levels and the decrease in exhaustion 
levels of tumor infiltrating cytotoxic T cells. Tumor immune-infiltration was thus analyzed 
by histologic analyses and specific cell isolation techniques needed to be developed. In addition, 
to verify our hypothesis that X-ray-induced TAM repolarization plays a major role in the 
synergic effect of the combined treatment, the model also needed to allow TAM isolation and 
the assessment of TAM polarization, considering technical limitations such as the very limited 
number of polarization markers that can be assessed by flow cytometry.  
 
 Once the syngenic mouse model of HNSCC was set up, the last objective of the project 
was to assess the role of X-ray irradiation and anti-PD-1 ICB play in the combined treatment. 
This for, mice were divided into treatment groups of untreated mice, mice treated by X-ray 
irradiation, mice treated by anti-PD-1 ICB and mice receiving the combined treatment. For each 
group, tumor infiltrating cytotoxic T cell activation and exhaustion have been assessed in 
parallel to TAM polarization.  
 
 The results of this work should lead to the setup of parameters allowing an optimized 


























1 Cell culture 
 
 Cal27 (human tongue squamous cell carcinoma, ATCC) and SQD9 (human laryngeal 
squamous cell carcinoma, a generous gift from Prof. Pierre Sonveaux, UCL) cells were 
maintained in culture in 75 cm2 polystyrene flasks (Corning), in 15 mL and 18 mL of Minimum 
Essential Medium (MEM-GlutaMAX, Gibco) respectively, supplemented with 10% fetal 
bovine serum (FBS, Thermo Fisher Scientific) at 37°C and 5% CO2. 
 
 SCC-VII (murine oral cavity squamous cell carcinoma, a generous gift from Prof. 
Olivier Feron, UCL) cells were cultured in 150 cm2 polystyrene flasks (Corning), in 45 mL of 
Minimum Essential Medium (MEM-GlutaMAX, Gibco), supplemented with 10% fetal bovine 
serum (FBS, Thermo Fisher Scientific) at 37°C and 5% CO2. 
 
 THP-1 (transformed human peripheral blood monocytes, ATCC) cells were cultured in 
75 cm2 polystyrene flasks (Corning) at 37°C and 5% CO2 using Roswell Park Memorial 
Institute 1640 Medium (RPMI) + L-Glutamine (Gibco) supplemented with 10% heat 
inactivated serum (HIS), 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES), 10 mM pyruvate, 2.5 g/L glucose and 50 nM ß-mercaptoethanol (supplemented 
RPMI medium).  
 
 L-929 murine fibroblasts were cultured in in 150 cm2 polystyrene flasks (Corning) at 
37°C and 5% CO2 using Dulbecco’s Modified Eagle’s Medium high glucose (DMEM high 
Glucose, Gibeco) supplemented with 10 mM pyruvate. To obtain L-929-conditioned medium, 
500 000 cells were seeded in 75 cm2 polystyrene flasks (Corning) containing 20 mL of 
supplemented medium. After 6 days, the supernatant was collected and frozen at -20°C for two 
months maximum.  
 
2 Cell counting 
 
 Cal27, SQD9 and SCC-VII cells were washed with sterile phosphate-buffered saline 
(PBS), then trypsinized. Cells were suspended in 10 mL of medium, collected in a 15 mL Falcon 
tube and centrifuged during 5 min at 1000 rpm. After removing the supernatant, the cell pellet 
was resuspended in 10 mL of MEM-GlutaMAX medium + 10% FBS. After homogenizing the 
suspension, 10 µL were mixed with 10 µL of Trypan Blue inside a 1mL tube. 10 µL of this mix 
were placed in a EVETM cell counting slide and analyzed by an automated cell counter 
(CountessTM Invitrogen). This counting was repeated two times and the average count of viable 
cells was calculated.   
 
 THP-1 cells are non-adherent cells and can directly be collected in a 15 mL Falcon tube, 
then centrifuged during 7 min at 1000 rpm. The following of the procedure was identical to the 




 L-929 murine fibroblasts were washed with sterile phosphate-buffered saline (PBS), 
then trypsinized. Cells were suspended in 10 mL of DMEM medium, collected in a 15 mL 
Falcon tube and centrifuged during 5 min at 1000 rpm. After removing the supernatant, the cell 
pellet was resuspended in 10 mL of DMEM medium + 10% FBS. After homogenizing the 
suspension, 10 µL were collected and placed on a Neubauer cell for manual cell counting.  
 
3 Macrophage polarization 
 
 To differentiate THP-1 cells into M0 macrophages, cells were seeded in 6-well-plates 
(Corning) at a density of 800 000 cells/well (1 600 000 cells/well for the irradiation) in  
3 mL/well supplemented RPMI medium containing 150 nM phorbol 12-myristate 13-acetate 
(PMA). 24 h later, the wells were washed with sterile PBS. Cells were then incubated in  
3 mL/well supplemented RPMI medium (without PMA). After 24 h, the medium was replaced 
by fresh supplemented serum-free RPMI medium containing 20 ng/mL IL-13 and IL-4 for M2 
polarization (during 48 h) or 10 pg/mL LPS and 20 ng/mL IFN-γ for M1 polarization (during 
24 h) (Genin et al., 2015). 
 
 Murine bone-marrow cells were isolated from femur diaphysis extracted from mice and 
maintained in culture in 10 cm2 Petri dishes (Corning) at 37°C and 5% CO2 in 8 mL of 
Dulbecco’s Modified Eagle’s Medium (DMEM, Gibco), supplemented with 10% HIS and 1% 
penicillin/streptomycin. After 24 h incubation, the medium containing non-adherent cells was 
collected and transferred into a new 10 cm2 Petri dish (Corning). The medium was then 
supplemented by 10% of L-929 murine fibroblast-conditioned medium to induce cell adhesion 
and differentiation into macrophages. After a 72 h incubation at 37°C and 5% CO2, the medium 
was replaced by 8 mL of fresh DMEM medium, supplemented with 10% FBS and 10% L-929-
conditioned medium for a 48 h incubation. The medium was then again replaced by fresh 
DMEM medium, supplemented with 10% FBS and 10% L-929-conditioned medium for a 48h 
incubation. At this stage, the differentiated bone marrow-derived macrophages (BMDMs) were 
either frozen at -80 °C in 90% HIS and 10% dimethyl sulfoxide (DMSO) or polarized into M1 
macrophages by 24 h incubation in DMEM medium + 10 % HIS + 10 ng/µL lipopolysaccharide 
(LPS) + 20 ng/µL murine IFN-γ or M2 macrophages by a 24 h incubation in DMEM medium 
+ 10 % HIS + 20 ng/µL murine IL-4 + 20 ng/µL murine IL-13. 
 
4 X-ray irradiation  
 
 For downstream RNA extraction, Cal27, SQD9 and SCC-VII cells were seeded in 6-
well plates (Costar) at a density of 250 000 cells/well and THP-1 cells at 1 600 000 cells/well. 
For downstream flow cytometry and western blot analysis, Cal27, SQD9 and SCC-VII cells 
were seeded in 25 cm2 polystyrene flasks (Corning) at a density of 520 000 cells/flask. 12 h 
after Cal27, SQD9 or SCC-VII cell seeding or at the completion of macrophage polarization, 





Figure 20. The irradiation chambers are composed of two stainless steel pieces covered by a mylar foil. 
 
Figure 21. Picture of the accelerator. 
 
 







































































































Figure 23. The cell irradiation station is equipped with a charged-couple device (CDD) camera, a passivated implanted planar 
silicon (PIPS) detector and a plastic scintillator BC-400. The XY motorized table allows the cartography of the beam in order 
to evaluate its homogeneity. (1) H+, He2+, C4+ broad beam; (2) vacuum chamber; (3) pumping system; (4) BC400 scintillator 
+ CCD camera fixed on a pneumatic jack; (5) PIPS detector placed on the left side of the beam for the dose-rate monitoring; 
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(PXI Precision X-ray). To obtain these doses, the generator was programmed at 225 kV and 
13.6 mA, a 2 mm aluminum filter was added to the collimator and the table was positioned at 
a distance of 50 cm beneath the source. These settings allow to obtain a dose rate of 2 Gy/min. 
Depending on the dose that was to be delivered, the duration of the irradiation was programmed 
to 0, 60, 150, 300 or 450s. A digital real-time dosimeter (PTW UNIDOS E) was used to monitor 
the dose rate during the irradiation.  
 
5 Proton irradiation 
 
 Irradiation chambers are composed of two stainless steel pieces, covered by a 3 µm thick 
mylar foil. The bottom and top parts make a sealed irradiation chamber thanks to a sealing joint. 
The irradiation procedure allows the production of a homogeneous broad beam of 1 cm2, placed 
at the center of the irradiation chamber (2 cm diameter) (Figure 20). In order for SCC-VII cells 
to adhere to the mylar foil, the center of the foil was coated with fibronectin during 40 min at 
37 °C. 50 000 cells were seeded in a 35µL drop of MEM medium supplemented with 10% of 
FBS and 1% penicillin/streptomycin on the fibronectin-coated surface. The irradiation 
chambers are incubated at 37°C for 5 h. The filling of the irradiation chambers (2 ml of 
supplemented medium) was made by one of the two holes located on the side, using a syringe. 
For the irradiation step, it is important to have a homogeneous monolayer of cells because the 
initial energy (1.3 MeV) of particles is not high enough to go through several layers of cells. In 
addition, this initial energy was determined to localize the Bragg Peak (LET = 25 keV/µm) and 
thereby the maximal relative biological effectiveness (RBE) into the nucleus of cells. Therefore, 
cells outside the field would not be irradiated. In order to irradiate the cells, the irradiation 
chambers containing the cells were placed on one of the four exit lines of the 2 MV accelerator 
(High Voltage Engineering Europa, ALTAIS), available at the LARN laboratory (University 
of Namur) (Figure 21). ALTAIS (for “Accélérateur linéaire Tandétron pour l’Analyse et 
l’Implantation des Solides”) allows the acceleration of ions from light weight (such as 
hydrogen) to heavy ones (such as uranium). A H+ homogenous broad beam from a TiH2 860 
source was used for the proton irradiation of SCC-VII cells. In more details, positive cesium 
steams sputter the TiH2 source and negatively ionize the hydrogen contained into the source. A 
plasma is thus created and the negative ions are extracted with a negative tension. The ions are 
then selected with a low energy magnet and accelerated in two times through a Tandetron 
accelerator (tandem acceleration). Indeed, negative ions are attracted by a high positive tension 
localized at the middle of the accelerator tube and undergo a first acceleration. In the middle of 
the accelerator tube, nitrogen, released by a stripper canal, elicits charge changes, making 
positive ions. H+ ions are then repulsed by the high positive tension and undergo a second 
acceleration. Finally, the accelerated ions are deflected with a high-energy magnet to the desire 
beam line. In our experiments, the left 10° beam line was used (Figure 22). Thanks to tools 
such as Bip Profil Monitor (BPM), the shape and the intensity of the beam were adjusted before 
and after the acceleration of particles, by playing on parameters such as the position of 
electrostatic lenses. Once the shape of the beam was adjusted, the homogeneity was tuned with 
a camera and detectors localized in the cell irradiation station (Figure 23), placed at the end of 




device (CCD) camera, that was used to shape the beam and to acquire a homogeneous beam. 
Passivated Implanted Planar Silicon (PIPS) detectors were placed before and after the cell 
irradiation station. They were used to tune the dose rate and to help ensuring the homogeneity 
and the stability of the proton beam (Figure 23) (Wéra A.-C., 2011). The H+ broad beam was 
thus homogeneous over 1 cm2 and went through a 1 µm thick Si3N4 exit foil. All these 
adjustments require several hours of settings before cell irradiation. The dose rate was fixed to 
2 Gy/min for the irradiation of SCC-VII cells.  
 
6 Total RNA extraction and RT-qPCR 
 
 The medium was removed from the 6-well plates and cells were lysed using 350 µL of 
RLT Lysis Buffer (Qiagen) and subsequent scrapping. Total RNA extraction from the lysates 
was performed using the RNeasy Mini Kit + DNAse (Qiagen) and the QIAcube device (Qiagen) 
following the supplier’s protocol.  
 
 After the extraction, the total RNA was either stored at -80°C or directly processed. 
RNA concentration was assessed using the ND-1000 Spectrophotometer and the Nanodrop 
1000 software (Isogen Life Science). Then, the appropriate volume was collected to contain  
2 µg of RNA and reverse transcription was performed using the GoScriptTM Reverse 
Transcription Mix, Oligo(dT) (#A2791, Promega) and the related instructions.  
 
 The cDNA was stored at -20°C or immediately diluted for subsequent qPCR analysis. 
cDNA from Cal27 and SQD9 cells was diluted at a ratio of 1:100 and cDNA from macrophages 
1:20 using ultrapure miliQ water. The amplification reaction mix contained 62.5% SYBRGreen 
PCR Master Mix (#4309155, Applied Biosystem) and 375 nM primers (Table 1). 16 µL of this 
mix were added in each well of a 96-well plate (Thermo Fisher Scientific) to 4 µL of cDNA. 
The plate was sealed, centrifuged during 1 min at 1200 rpm and analyzed by a ViiA™ 7 Real-
Time PCR System (Thermo Fisher Scientific). Thermal cycling was based on an initial 
denaturation step at 95°C for 5 min followed by 40 cycles at 95°C for 30 sec and 60°C for  
1 min. 
 
Gene Supplier Forward Primer Reverse Primer 
h_23kDa IDT GCCTACAAGAAAGTTTGCCTATCTG TGAGCTGTTTCTTCTTCCGGTAGT 
h_CCL22 IDT CACTTCTACTGGACCTCAGAC AGTAGGCTCTTCATTGGCTCA 
h_CD206 IDT GCTAAACCTACTCATGAATTACTTACAACAA GAAGACGGTTTAGAAGGGTCCAT 
h_IL-10 IDT CTGGAAACATCTGGAGAGAGGAA GTAGATGCCTTTCTCTTGGAGCTTA 
h_IL-6 IDT CCTGAACCTTCCAAAGATGGC CACCAGGCAAGTCTCCTCATT 
h_IL-8 IDT TCTGTGTGAAGGTGCAGTTTT GGGGTGGAAAGGTTTGGAGTA 
h_PD-L1 IDT GACATGTCAGGCTGAGGG TCCTCTCTCTTGGAATTGGTGG 
h_RPS9 IDT CTGGATGAGGGCAAGATGAAG GTCTGCAGGCGTCTCTCTAAGAA 
h_TGF- "1 IDT AGGGCTACCATGCCAACTTCT CCGGGTTATGCTGGTTGTACA 
h_TNF- & IDT TTGATCCCTGACATCTGGAATCT CTGGAAACATCTGGAGAGAGGAA 
m_PD-L1 IDT GCTCCAAAGGACTTGTACGTG TGATCTGAAGGGCAGCATTTC 
m_23kDa IDT GAGGTCGGGTGGAAGTACCA TGCATCTTGGCCTTTTCCTT 




Figure 24. X-ray irradiation of tumor bearing mice. The irradiation table is placed at 40 cm believe the source. The mice 
were place n prone position on a 5 cm thick gel pack placed on the irradiation table and an adjustable collimator used for X-














7 Immunofluorescence labeling and confocal microscopy  
 
 Cal27 and SQD9 cells were seeded at 30 000 cells/well in 24-well plates containing a 
glass coverslip. Cells were fixed during 15 min with paraformaldehyde 4% in PBS at room 
temperature and then permeabilized with ice cold pure methanol for 10 min at -20°C. Cells 
were rinsed one time with PBS for 5 min and blocked by a blocking buffer (1X PBS + 5% 
normal serum + 0.3% Triton™ X-100) during 60 min. Cells were then incubated overnight at 
4°C with the primary antibody (Table 2). Primary antibodies were 1:200 (PD-L1) diluted in 
PBS + 1% BSA + 0.3% Triton X-100. Cells were rinsed three times with PBS for 5 min each 
and then incubated for 1.5 h with secondary antibody 1:1000 diluted (Anti-Rabbit IgG (H+L), 
F(ab')2 Fragment (Alexa Fluor® 488 Conjugate) #4412) at room temperature. After washing 
the cells three times with PBS, nuclei were stained with TOPRO-3 (1:80 diluted in RNAse 
solution). Cells were then washed three times with PBS. The coverslips were mounted using 
Mowiol (Sigma) and cells were observed with a confocal microscope (SP5, Leica). 
Protein Primary antibody Secondary antibody 
PD-L1 Anti-PD-L1 (D8T4X)  
(Rabbit, Cell Signaling Technology #86744, 1/1000) 
Anti-rabbit-Alexa 488 nm 
(Goat, Thermo Fisher Scientific A-11008, 1/1000) 
 
Table 2. Antibodies used for immunofluorescence labeling 
 
8 Mouse model and in vivo experimentation  
 
 Sixty-seven 6 weeks old C3H/HeN mice were purchased from Charles River 
Laboratories (Brussels, Belgium). Housing, maintenance and experimentation were performed 
according to the regulations approved by the local ethics committee for animal experiments of 
the University of Namur (AR 18/326, Appendix 1 and 2). After a 1 week resting period, mice 
were anesthetized by isoflurane inhalation (2.5%, Zoetis), their right flank shaved and 
disinfected before receiving the injection of SCC-VII cancer cells (number adjusted to the 
experimental group, as detailed in Appendix 1 and 2) subcutaneously in a total volume of  
150 µL of PBS. After reaching a final tumor volume of 250 mm3 or 350 mm3 depending on the 
experimental group (Appendix 1 and 2), mice were anesthetized by intra-peritoneal injection 
with Ketamine 100 mg/kg (Dechra) and Xylazine 10 mg/kg (VMD Livestock Pharma) and 
placed in prone position on 5 cm thick heated gel packs located on top of the irradiation table 
(Figure 24). To irradiate the tumors with a dose of 10 Gy, the generator was programmed at  
225 kV and 14.5 mA, a 5 mm copper filter was added to the collimator and the table was 
positioned at a distance of 40 cm beneath the source. These settings allow to obtain a dose rate 
of 2 Gy/min. An adjustable collimator was added at the exit of the source, to focalize the 
radiation beam on the tumor (Figure 24). Mice were irradiated during 300 s to deliver a dose of 
10 Gy. After the irradiation, depending on the experimental group, mice were injected with  
10 mg/kg of anti-PD-1 antibodies i.p. (#114114, Biolegend). 72 h after the injection, mice were 
anesthetized by an i.p. injection of 100 mg/kg Ketamine (Dechra) and 10 mg/kg Xylazine 
(VMD Livestock Pharma) and euthanized by cardiac puncture followed by cervical dislocation. 




to the tumor, distant lymph nodes in the axillary and mandibular region as well as both femur 
diaphysis.  
 
9 Tumor dissociation – TIL and TAM isolation 
 
 Tumors were dissociated with the tumor dissociation kit (#130-096-730, Miltenyi 
Biotec) and the gentleMACS octo dissociator with heaters (Miltenyi Biotec) following 
manufactor’s instructions.  The single cell suspension was then filtered on a 70 µm smartStainer 
(#130-098-462, Miltenyi Biotec), collected in a 15 mL Falcon tube and centrifuged at 300g  
4 °C for 7 min. Cells were resuspended on ice by cold PBS supplemented by 2 mM EDTA and 
0.5% BSA (MACS buffer). A 1 mL sample was taken to perform automated cell counting as 
prescribed previously. The cell suspension was centrifuged at 300g 4 °C for 7 min. and 
resuspended in 90 µL of MACS buffer per 107 cells. Per 107 cells, 10 µL of CD8 TIL 
microbeads (#130-116-478, Miltenyi Biotec) were added and the cell suspension mixed before 
15 min incubation at 4°C. 500 µL of MACS buffer were added per 107 cells. A LS column 
(#130-042-401, Miltenyi Biotec) was placed in the magnetic field of the MACS multistand 
separator (1130-042-303, Miltenyi Biotec) and washed by 3 mL of MACS buffer. A 30 µm 
smartStainer (#130-098-458, Miltenyi Biotec) was placed on top of the LS column and the cell 
suspension dropped on the smartStainer. The column was rinsed twice by 1 mL of 
MACSbuffer, before removing the CD8- fraction. The LS column was removed from the 
magnetic field, placed on a new 15 mL falcon and flushed by 3 mL of MACSbuffer using the 
piston associated to the column. The CD8+ fraction was put on ice, while the CD8- fraction 
was centrifuged at 300 g 4°C for 7 min., resuspended in 90 µL of MACS buffer per 107 cells 
and added by 10 µL of anti-F4/80 TAM microbeads (##130-110-443, Miltenyi Biotec). This 
mix was incubated for 15 min at 4°C, then added with 2 mL of MACS buffer and centrifuged 
at 300g 4°C for 7 min. The labeled cells were resuspended in 500 µL of MACS buffer per 107 
cells and isolated on a new LS column as previously described. 
 
10 Flow cytometry 
 
 CD8+ TILs, F4/80+ TAMs, CD8- F4/80- tumor cells and SCC-VII cells were 
centrifuged at 300g 4 °C for 10 min. CD8+ TILs were resuspended in 74 µL of MACS buffer 
and labeled by 2 µL CD45-APC-Vio770, 10 µL CD3-VioBlue, 2 µL CD8-PE-Vio770, 10 µL 
CD25-VioBrightFITC, 2 µL CD69 and 2 µL PD-1 (Table 4). F4/80+ TAMs were resuspended 
in 80 µL of MACS buffer and labeled by 2 µL CD45-VioBlue, 2 µL F4/80-APC, 2 µL CD11b-
VioBirghtFITC 10 µL Ly6G-PE-Vio770, 2 µL Ly6C-PE and 2 µL MHC-II-APC-Vio770 
(Table 4). CD8- F4/80- tumor cells and SCC-VII cells were resuspended in 97 µL of MACS 
buffer and labeled by 3 µL of PD-L1 (Table 4). After 15 min. of incubation at 4 °C in the dark, 
cells were washed by 2 mL of MACS buffer and centrifuged 10 min. 300 g at 4 °C. All cells 
were resuspended in 500 µL of MACS buffer before being analyzed by FACS Verse (BD 





Target protein Supplier Fluorochorme  Reference number 
CD45 (TILs) Miltenyi Biotec APC-Vio770 130-110-662 
CD45 (TAMs) Miltenyi Biotec VioBlue 130-110-664 
CD3 Miltenyi Biotec VioBlue 130-114-519 
CD8 Miltenyi Biotec PE-Vio770 130-110-680 
CD25 Miltenyi Biotec VioBright-FITC 130-108-999 
CD69 Miltenyi Biotec APC 130-115-461 
PD-1 Miltenyi Biotec PE 130-111-800 
F4/80 Miltenyi Biotec APC 130-116-547 
CD11b Miltenyi Biotec VioBright-FITC 130-113-243 
Ly6G Miltenyi Biotec PE-Vio770 130-107-915 
Ly6C Miltenyi Biotec PE 130-111-778 
MHC-II Miltenyi Biotec APC-Vio770 130-112-233 
CD80 Miltenyi Biotec APC-Vio770 130-116-463 
m_PD-L1 BioLegend PE 329705 
h_PD-L1 Cell Signalling / 86744 
Rabbit mcAb Thermo Fisher Scientific Alexa 488 A-11008 
Table 3. Antibodies used for flow cytometry analyses 
 
11 Tissue preparation for histologic analyses and 
immunolabeling 
 
 After their resection, tumors, spleens and lymph nodes chosen for histologic analysis 
were rinsed three times in a 0.9% NaCl solution before being placed in an embedding cassette 
and emerged for 24 h into formaldehyde 10%. After fixation, the samples were dehydrated by 
four consecutive baths of methanol 100% at 35°C and transformed into an organic phase by 
two 45 min and two 60 min incubations in toluene 100% at 35°C. Samples were then immerged 
four times 60 min into paraffin at 60°C before being cooled down to room temperature to form 
solid paraffin blocks containing the samples, ready for microtomisation (RM2145, Leica) into 
6 µm thick slices and transferred onto microscope slides (#631-0108, VWR).  
 
12 Hemalun-Erythrosin-Safran staining 
 
 Once transferred tonto microscope slides, they were dried to 42°C during 90 min, before 
being deparaffinized by two baths of 3 min toluene. Rehydration occurred by immersion two 
times 3 min in absolute methanol and one time 3 min methanol 70 %. The sides were bleached 
during 10 min in tapped water, before 7 min nuclear staining with hemalun. Then slides were 
rinsed during 1 min with tapped water and dedifferentiated during 2 min in HCL-ethanol and 
rinsed again for 10 min in tapped water. A 6 min bath in erythrosine allowed cytoplasmic 
staining, followed by 1 min rinsing in tapped water. Slides were dedifferentiated for 1 min in 
ethylene alcohol 70% and dehydrated during three bathes of 30 seconds each in absolute 




by three times 30 seconds rinsing in absolute isopropylic alcohol. At this point, microscopic 
slides were immerged in toluene before adding DPX and a coverslip in top of the tissue. 
Samples were pressed and dried during 24 h before microscopic analysis.    
 
13 Immunohistofluorescence  
 
 Samples on microscopic slides were deparaffinized and bleached by consecutive baths 
of two times 3 min toluene, two times 3 min methanol 100%, one time 3 min methanol 70% 
and one time 10 min tapped water. Epitope retrieval was achieved by a 20 min incubation in 
0.21% citric acid pH 6 at 95°C. Samples were then rinsed by PBS and incubated into two times 
3 min glycine 0.1 M followed by another PBS rinsing before blocking through a 1 h incubation 
in a blocking buffer (PBS - BSA 0.2%). The samples were incubated with the primary antibody 
(Table 5) at 4°C overnight. The microscope slides were then washed three times 3 min with the 
blocking buffer before a 1 h incubation with the corresponding secondary antibody. Next, the 
microscope slides were washed three times with the blocking buffer before 15 min nuclear 
staining by Hoechst (1/100) (33258, Sigma Aldrich) and three times 3 min rinsing with PBS. 
Cover slides were then mounted using DPX (#1.005790500, Merk). 24 hours later, the samples 
were analyzed using a fluorescence microscope (BX63, Olympus). 
 
Protein Primary antibody Secondary antibody 
CD3 Anti-CD3  
(Rabbit, Abcam, #ab56290, 1/50) 
 
 Anti-rabbit-Alexa 568 nm 
(Goat, Thermo Fisher Scientific, #A-11011, 1/1000) 
 
F4/80 Anti-F4/80 (RM0029-11H3) 
(Rat, Abcam, #ab56297, 1/50) 
 
Biotinylated anti-rat IgG 
(Goat, Vector Laboratories #BA-9400, 1/50) 


















































Figure 25. mRNA expression of macrophage polarization markers in M2 and M1 macrophages normalized to unpolarized 
M0 macrophages. THP-1 cells were differentiated into MO macrophages, which were then polarized into either M1 or M2 
macrophages. After total mRNA extraction, the relative mRNA expression of specific polarization markers normalized by 
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Figure 26. mRNA expression of PDL-1 in Cal27 (A) and SQD9 (B) cells as well as M2 (C) and M1 (D) macrophages and SCC-
VII cells (E) after X-ray irradiation or proton irradiation of SCC-VII cells (F) normalized to non-irradiated control cells at  
24 h. Cells were irradiated at 0 Gy, 5 Gy, 10 Gy and 15 Gy and cancer cells additionally at 2Gy. Total mRNA extraction was 
performed 24, 48 and 72 h after irradiation for Cal27, SQD9 and SCC-VII cells and 24 and 48 h after irradiation for M2 and 
M1 macrophages. The relative mRNA expression of PD-L1, normalized to the expression of 23 kDa for Cal27, SQD9 and SCC-
VII cells and RPS9 for M2 and M1 macrophages, was determined by RT-qPCR. Statistical analyses consist of a two-way ANOVA 
test. #, ##, ###, ####: significantly different from control condition respectively with p<0.05, p<0.01, p<0.001 and p<0.0001; 















1 In vitro assessment of PD-L1 expression after 
irradiation 
 
1.1 Macrophage polarization 
 
 THP-1 monocytes were differentiated into M0 macrophages by incubating them in the 
presence of phorbol-12-myristat-13-acetate (PMA) during 24 h followed by a 24 h incubation 
in PMA-free medium. M0 macrophages were then polarized either during 48 h in the presence 
of IL-13 and IL-4 into anti-inflammatory M2 macrophages or during 24 h in the presence of 
LPS and IFN-γ into pro-inflammatory M1 macrophages. The expression of specific polarization 
markers was assessed by RT-qPCR to determine if the polarization was successful. The results 
indicated an increased expression of CCL22, CD206 and IL-10 mRNA for M2 macrophages 
and an increased expression of IL-6, IL-8 and TNF-& mRNA for M1 macrophages (Figure 25), 
confirming the successful macrophage polarization. 
 
1.2 PD-L1 induction by X-ray irradiation 
 
 In order to investigate the effects of X-ray irradiation on PD-L1 expression, Cal27 and 
SQD9 cells were irradiated at different doses (0 Gy, 5 Gy, 10 Gy, 15 Gy) and the expression of 
PD-L1 was assessed by RT-qPCR and flow cytometry at different timings post-irradiation (pi. 
24, 48, 72 h). At mRNA level, the most significant increase for SQD9 cells was obtained 72 h 
after 5 Gy irradiation. For Cal27 cells, the highest significant increase was observed 48 h pi. 
after irradiating cells at a 5 Gy dose (Figure 26A and B). 
 
  The mRNA expression of PD-L1 was also analyzed in THP-1-derived M2, M1 and M0 
macrophages. Considering that 72 h pi. the macrophage polarization was not maintained (data 
not shown), the expression of PD-L1 was only assessed 24 h and 48 h after irradiation. While 
the results indicate a slight decrease in PD-L1 expression at 48 h compared to 24 h, no 
significant increase was observed neither for M2 macrophages nor M1 macrophages, at all 
doses (Figure 26C and D).  
 
 Since future in vivo experiments first need to be performed in mice before being tested 
on human, the mRNA expression of PD-L1 was additionally assessed in SCC-VII cells. These 
cells were also used to compare the impact of proton vs photon irradiation on PD-L1 expression 
as well as the previously described PD-L1 induction pathway by DDR. PD-L1 expression was 
assessed at 24, 48, 72 h after 0 Gy, 2 Gy, 5 Gy, 10 Gy, 15 Gy irradiation. While for SCC-VII 
cells, significant dose- and time-dependent increases could be observed after X-ray irradiation 
(Figure 26E), there was no PD-L1 induction following proton irradiation (Figure 26F).  
 
 In preparation of the in vivo part of this project, the optimal conditions to administrate 
an anti-PD-1 antibody to the mice needed to be determined. Since it is necessary, in order to 





Figure 27. Analysis of PD-L1 protein expression and subcellular localization in Cal27 (A) and SQD9 (B) cells. Cells were 
irradiated at 0 Gy and 5 Gy and fixed after 48 h before anti-PD-L1 labeling and nuclear staining. Confocal microscopy was 








Figure 28. Relative protein expression of PD-L1 at the membrane of Cal27 (A), SQD9 (B) and SCC-VII (C) cells after X-ray 
irradiation normalized to non-irradiated control at 24 h. All cells were irradiated at 0 Gy, 2Gy, 5 Gy, 10 Gy and 15 Gy.  
PD-L1 expression was analyzed by flow cytometry 24, 48 and 72 h after irradiation. Results are expressed as relative to the 
non-irradiated control cells at 24h pi. Statistical analyses consist of a two-way ANOVA test. #, ##, ###, ####: significantly 
different from control cells (0 Gy 24 h) respectively with p<0.05, p<0.01, p<0.001 and p<0.0001; Results are presented as 
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membranes only, confocal microscopy after immunofluorescence labeling of PD-L1 was 
performed to visualize and localize the PD-L1 protein following X-ray irradiation (Figure 27A 
and B). On one hand, the results confirmed the increase in PD-L1 expression after X-ray 
irradiation and on the other hand, they confirmed that the increase was not restricted to the 
endoplasmic reticulum but that it was clearly observed at the cell plasma membrane.  
 
 Hence flow cytometry was performed to assess the induction fold of PD-L1 on cell 
membranes of Cal27, SQD9 and SCC-VII cells. While proton irradiations still remain to be 
performed, a significant dose- and time-dependent increase in the relative PD-L1 abundance on 
the cell surface was observed in all three HNSCC cell lines (Figure 28A, B and C), from 24 h 
to 72 h. These results suggest that this dose- and time-dependent effect, needs to be considered, 
in order to chose the appropriate timing when using an anti-PD-1 immune-checkpoint blockage 






Figure 29. Experimental strategy of in vivo pilot project. Twenty-seven mice were divided into 3 groups of 9 mice that were 
injected with either 250 000 cells, 500 000 cells or 1 000 000 cells. Each of these 3 groups was subdivided into 3 subgroups of 
3 mice, one control group that was not to be treated, 1 subgroup that was to be irradiated once tumors grew up to 250 mm3 
and 1 subgroup that was to be irradiated once tumors grew up to 350 mm3. 72h after achieving the tumor size of 250 or  




2 Set up of a syngenic in vivo mouse model of HNSCC  
 
2.1 Context  
 
 A syngeneic mouse model of HNSCC using C3H/HeN mice injected subcutaneously 
with SCC-VII cells was chosen for the study of the impact of macrophage repolarization on 
anti-PD-1 ICB efficiency, when using the combined treatment of X-ray irradiation and an anti-
PD-1 antibody. First, a pilot project was set up to determine three parameters necessary for the 
main project: the optimal number of cancer cells to be injected to result in the formation of 
tumors within an acceptable delay (less than 8 weeks); the immune infiltration and the 
homogeneity of the immune cell’s spread throughout the subcutaneous tumors, to allow 
arbitrary cutting of the tumors into three pieces for down-stream analysis; the minimal required 
tumor volume at the time of the treatment (250 or 350 mm3, 72 h before the sacrifice) to perform 
TIL and TAM isolation for flow cytometry analysis, tumor RNA extraction and histologic 
analysis. To this aim, 27 mice were divided into three experimental groups according to the 
number of injected SCC-VII cells (250 000, 500 000 or 1 000 000). Each group was subdivided 
into three subgroups, one unirradiated subgroup, one irradiated subgroup with 250mm3 tumors 
and one irradiated subgroup with 350mm3 tumors. Each subgroup contained three mice  
 
Figure 29). Of these three mice, one was intended to histologic analysis only, one to isolation, 
RNA extraction and histologic analysis and one backup in case a mouse does not develop a 
tumor. Additional information and practical information can be found in the ethics protocol as 
authorized by the local ethics committee (Appendix 1). 
 
2.2 Tumor development 
 
 In the group that was injected with 1 000 000 cells, 89% of the mice developed tumors 
after less than 8 weeks. In the groups injected with 500 000 and 250 000 cells, only 44% and 
56% of the mice respectively developed tumors within the defined timeframe.  
 
 Even though some tumors were spherical, most tumors were either oval or 
multispherical. Hence, tumor volumes needed to be calculated differently. For spherical, oval 
and multipherical tumors, the volume was calculated as descripted in formulas 1, 2 and 3 
respectively:  
 
Formula 1:  ' = 	 *+	×	-	×	./0123
*  
 









Figure 30. Macroscopic tumor analysis. Tumors are measured before resection (A). Macroscopic analysis show blood vessels 
at the surface of the tumor (B), tumor invading nearby muscles forming tight adhesions (C), visible hemorrhagic areas at the 
surface (D) and hemorrhagic zones inside the tumor (E). Spleen (green border), distant lymph node extraction (blue border) 






Figure 31. Vascularization and immune infiltration throughout tumors of untreated mice. HES stained tumors tissue. A: intra-
tumoral hemorrhage and consequent erythrocyte and immune infiltration. B: magnification of perihemorrhagic erythrocyte 
and immune-infiltration (arrows). C: intra-tumoral blood vessel and erythrocytes. D: intra-tumoral immune-infiltration. 











Figure 32. Topologic analysis of HES stained tumor sections (A-G) and tumor distant lymph nodes (H) of untreated mice. 
Cancer cells (black arrow) can be identified by anisocytosis, anisocaryosis, the presence of multiple nucleoli, increased nucleus 
to cytoplasm ratio, polyploïdi and projecting nucleoli (A and B). Tumor periphery contain very high numbers of immune cells 
infiltrating as well the tumor as the surrounding adipose tissue (C). Invasion of abdominal muscles (black arrows) by cancer 
cells (D). Necrotic area at the tumor periphery (green border) (E). Cancer cells undergoing apoptotic mitosis (black arrows) 
and apoptosis (white arrows). Cancer cells at tumor periphery presenting an altered, mesenchymal-like morphology (G). 
Important cancer cell infiltration at proximity to the connective capsule of a tumor distant lymph node (H). Magnification: 4x 




Figure 33. Cytotoxic T cell infiltration of the tumor. CD3+ immunolabeling of cytotoxic tumor infiltrating T cells (red) 
showing a high degree of T cell infiltration and overall homogeneous spread throughout the tumor. Nuclei were stained by 




Figure 34. Abdominal lymph node adjacent to the tumor. HES stained section of the tumor and associated lymph node of an 
untreated mouse. The tumor (T) and lymph node (LN) are surrounded by fat tissue rich in blood vessels (A). The inside of the 
adjacent lymph node rich in immune cells showing cancer cell invasion (B). Tumor periphery at proximity to blood vessels of 









 In order to divide the resected tumors into three parts, one for histologic analyses, one 
for TIL and TAM isolation and the third one for tumor RNA extraction, 250 mm3 at the time of 
the treatment (72 h before the sacrifice, untreated mice included) was insufficient, since the 
number of isolated TILs and TAMs was too low to perform flow cytometry analysis. Enough 
cells could be isolated from 350 mm3 (72 h before the sacrifice, untreated mice included) big 
tumors (data not shown). Tumor samples for RNA isolation were stored at -72°C after snap 
freezing in liquid nitrogen and still need to be processed.  
 
2.3 Histologic features 
 
 As mentioned previously, from one mice of each subgroup, the entire tumor was used 
for histologic analyses. Tumor were measured and macroscopic analysis performed (Figure 30 
A). The presence of blood vessels was confirmed of all tumor but the density was variable 
(Figure 30 B). Most tumors had, by the time of the resection, formed tight adhesions with 
nearby muscle tissue (Figure 30 C), making it difficult to resect tumors tissue only. In some 
cases, at the surface of a tumor and the inside, hemorrhagic areas were found, that could later 
be seen in histology too (Figure 30 D and E). In addition to the tumor, femurs, distant lymph 
nodes (LNs) and the spleen were resected for downstream histologic analysis (Figure 30 F). 
After tumor resection, HES staining was performed to visualize the overall morphology of the 
different tissues that were taken, while immunofluorescence labelling of CD3+ T cells allowed 
the assessment of the immune infiltration and its homogeneity throughout the tumor. 
Immunohistochemistry staining of F4/80+ macrophages is beeing performed as well but the 
technique needs to be improved. HES stained histologic analyses for tumors showed, rich 
vascularization and possible hemorrhages as well as high immune cell infiltration inside the 
tumor (Figure 31 A, B, C and D). Cancer cells can be easily identified by the presence of 
irregularly shaped cell membranes and nuclei, anisocytosis, anisocaryosis, an increased nucleus 
to cytoplasm ratio, high rate of mitosis, polyploïdi or projecting nucleoli (Figure 32 A and B). 
In the periphery of tumors as well as the surrounding fat tissue, a strongly enriched immune 
infiltration was observed (Figure 32 C). In the same area of the tumors, for those who formed 
tight adhesions with nearby muscles, histologic analysis reveal muscle infiltration by cancer 
cells indicating a high degree of invasiveness (Figure 32 D). Most tumors present to some 
extend necrotic areas that are visible microscopically only, as well as a large number of isolated 
apoptotic cancer cells as well as cancer cell in apoptotic mitosis (Figure 32 E and F). In the 
periphery of many tumors, independently weather mice were treated, cancer cells can be found 
that have a very different morphology and a mesenchymal-like phenotype (Figure 32 G). 
Analysis of distant lymph nodes show early stage cancer cell infiltration (Figure 32 H). 
Immunofluorescence labeling of CD3+ T cells showed a high degree of T lymphocyte 
infiltration as well as a homogeneous spread of T cells throughout the tumor (Figure 33). For 
some tumors that were entirely aimed for histologic analysis, during the resection, the lymph 
node adjacent to the tumor and that was included in the same fat tissue with the tumor was 
isolated together with the tumor. Microscopic slices of these samples (Figure 34 A) show cancer 





Figure 35. Schematic representation of T cell activation analysis by flow cytometry. SCC-A and FSC-A were used to gate on 
cells. Singlets were selected by FSC-H over FSC-A. Propidium iodide and CD45 allowed to gate on living leukocytes (PI- 
CD45+), from which cytotoxic T cells could be isolated (CD3+ CD8+). Early and late activation of these cytotoxic TILs was 




Figure 36. Schematic representation of TAM polarization analysis by flow cytometry. SCC-A and FSC-A were used to gate on 
cells. Singlets were selected by FSC-H over FSC-A. Propidium iodide and CD45 allowed to gate on living leukocytes (PI- 
CD45+), from which myeloid cells could be isolated (F4/80+ CD11b+). Contaminating neutrophils were gated out as Ly6G+. 
Immature myeloid cells (Ly6Ghigh) were distinguished from mature macrophages (Ly6Glow) and macrophage polarization 




Figure 37. Flow cytometry analysis of the percentage of PD-L1 over-expression CD8- F4/80- tumor cells 72 h after X-ray 
irradiation (RX) compared to untreated group (CTL). Statistical analysis consists of unpaired t-test. ****: significantly 






























periphery at proximity to blood vessels contained in the fat tissue (Figure 34 C). The samples 
were used as positive control for both HES staining and CD3-immunolabelling of lymphocytes. 
Similarly to what was observed at proximity to tumor infiltrating blood vessels, a particularly 
rich infiltration of immune cells was observed at the periphery of the tumors (Figure 32 C and 
Figure 34 C).  
 
2.4 Flow cytometry set up 
 
 The in vivo pilot project also allowed the establishment of optimal reference settings for 
flow cytometry analysis of TAM polarization and TIL activation after TIL and TAM isolation 
from the tumors. To assess the activation of tumor infiltrating cytotoxic T cells, living tumor 
infiltrating T cells (CD45+ CD3+ PI-) were gated in during flow cytometry. CD8+ cytotoxic 
TILs were analyzed for early activation (CD25), late activation (CD69) and exhaustion (PD-1) 
(Figure 35). In order to determine TAM polarization, living myeloid cells (CD45+ CD11b+ 
F4/80+ PI-) were selected during flow cytometry. Contaminating neutrophils (Ly6Ghigh) were 
gated out. In the resulting population, immature myeloid cells (Ly6Chigh) were distinguished 
from macrophages (Ly6Clow), whose polarity was then determined by MHC-II. M1 
macrophages were selected as MHC-IIhigh and M2 macrophages MHC-IIlow (Figure 36).  
 
 We also assessed the PD-L1 expression in CD8- and F4/80- tumor cells by flow 
cytometry to verify if the X-ray induced-PD-L1 overexpression observed in vitro could be 
confirmed in vivo. The results show a significant increase in PD-L1 expression in tumor cell 





 Altogether, these results confirm that injecting 1 000 000 cells and growing tumor up to 
350 mm3 before treatment allow RNA extraction, histologic analysis and sufficient TIL and 
TAM isolation for flow cytometry analysis in both irradiated and non-irradiated mice. During 
these experiments, in all mice, no signs of discomfort or pain could be observed except for one 






Figure 38. Workflow of the main in vivo project. Mice were divided into 4 groups of 10 mice each and they were injected with  
1 000 000 SCC-VII cells subcutaneously into the right flank. Once a tumor reached the volume of 350 mm3, the mouse was 
depending on the experimental group, either untreated, treated by a 10 Gy irradiation of the tumor or injected intraperitoneally 
with the anti-PD-1 antibody (10 mg/kg). The untreated mice, as well as the X-ray only and anti-PD-1 only mice were sacrificed 
72 h later. Seventy-two hours after X-ray irradiation, mice receiving the combined treatment were injected with the anti-PD-1 





Figure 39. Evaluation of TIL activation and exhaustion by flow cytometry. Early activation was determined by CD25 (A). Late 
activation (B) and exhaustion (C) of CD8+ living cytotoxic T cells were defined by CD69 and PD-1 respectively. Statistical 
analyses were performed using one-way ANOVA. #, ##, ###, ####: significantly different from control condition (CTL) 
respectively with p<0.05, p<0.01, p<0.001 and p<0.0001; Results are presented as mean ± SD. 
  
 





















































































































Figure 40. Evaluation of TAM polarization by flow cytometry. M2 macrophages (A) are characterized by high expression of 
MHC-II, while M1 macrophages (B) express low levels of MHC-II. Statistical analyses were performed using one-way ANOVA. 
# and ##: significantly different from control condition (CTL) respectively with p<0.05 and p<0.01. Results are presented as 



























































































3 In vivo investigation of radiation-induced TAM 
repolarization to enhance anti-PD-1 ICB  
 
  
3.1 Context  
 
 After establishing the syngeneic mouse model of HNSCC using C3H/HeN mice injected 
subcutaneously with 1 000 000 SCC-VII to grow tumors of 350 mm3, a second project was 
launched in order to investigate the impact of radiation-induced macrophage repolarization on 
cytotoxic T cell activation and anti-PD-1 immune checkpoint blockage efficiency. For this 
purpose, 40 mice were split into 4 groups, one untreated, one treated by a focalized 10 Gy X-
ray irradiation, one treated by an anti-PD-1 antibody and one receiving the combined treatment 
of X-ray irradiation and the anti-PD-1 antibody (Figure 38). For this project, treatment 
efficiency was defined by the level of early activation, late activation and exhaustion of living 
tumor infiltrating cytotoxic T cells (CD45+ CD3+ CD8+ PI-) using flow cytometry (Figure 35). 
For this, CD25 and CD69 were used as early and late activation markers respectively, while 
PD-1 was used an exhaustion marker. To assess macrophage polarization, CD11b + and F4/80+ 
myeloid cells were gated in from CD45+ and propidium iodide negative living leukocytes. 
Contaminating neutrophils were gated out as Ly6G positive and mature and immature myeloid 
cells were distinguished as Ly6Clow and Ly6Chigh respectively. MHC-II then served as 
polarization marker for M1 (MHC-IIhigh) and M2 (MHC-IIlow) macrophages (Figure 36). 
Additional information and practical information can be found in the ethics protocol as 
authorized by the local ethics committee (Appendix 2). 
 
3.2 Treatment effects 
3.2.1 Effects on TIL activation and exhaustion 
 
 Compared to the untreated group, early TIL activation was significantly increased in 
tumors of mice treated by X-rays only (Figure 39A). A significant increase in late TIL 
activation was observed in all treated groups (Figure 39B). The only significant decrease in TIL 
exhaustion was evidenced in mice treated with the anti-PD-1 antibody alone (Figure 39C). For 
the assessment of all three activation markers, lymphocytes isolated from peripheral blood 
mononuclear cells isolated from the mice blood on a Ficoll gradient after cardiac puncture was 
used as negative control (data not shown). 
 
3.2.2 Effects on TAM polarization 
 
 While anti-PD-1 treatment alone decreased the proportion of M2 polarized macrophages 
and favored M1 macrophage polarization, X-ray-treated mice as well as mice that received the 
combined treatment showed an increase in the proportion of M2 macrophages and a decrease 
in M1 macrophages (Figure 40A and B). For the assessment of the macrophage polarization, in 




femurs, were used as controls for M1 and M2 macrophages during flow cytometry analysis 





























Figure 41. Schematic representation of the expected effect of a combination therapy of ICB and radiotherapy in HNSCC 
treatment. Conventional therapies present very high efficiency at early stages of treatment, while ICB, at early stages, seem to 
have very little impact on patient survival. The overall survival is however only slightly increased for conventional therapies, 
whereas ICB lead to long-term beneficial effects and disease-free survival for some patients. Combined therapies summon the 
advantages of both ICB and conventional therapy, leading to a high initial efficiency and a significantly increased overall 
survival and disease-free survival for a significantly increased number of patients suffering from HNSCC. (adapted from: 
Champiat et al., 2014) 
Discussion	and	Perspectives	
	 36	
 The capacity of cancer cell to express the immune-modulator PD-L1 and to repolarize 
TAM towards an M2-like phenotype are two mechanisms that allow them to create an immuno-
suppressive TME and to evade immune destruction. This process significantly promotes tumor 
growth, cancer cell resistance and poor patient outcome. Targeting these immuno-modulatory 
mechanisms in cancer therapy can alleviate immuno-suppression and promote efficient cancer 
cell eradication and improve patients’ response to treatment. In this immuno-modulatory 
context, radiotherapy induces immunogenic cell death and macrophage repolarization towards 
an M1-like phenotype in vitro, but it also induces, via DDR, an increased expression of the 
immuno-suppressor PD-L1 in a dose and time-dependent manner (Krysko et al., 2012; Klug et 
al., 2013; Sato et al., 2017; Figures 26, 27 and 28). Radiotherapy as well as anti-PD-1 ICB 
present both immuno-stimulating properties, which, when used optimally in combination, could 
explain at a molecular level a potential synergic effect in HNSCC treatment, as it has been 
described in pre-clinical models and in clinics for various combinations of ICB with 
conventional treatments. Unlike conventional therapies, ICB is at short-term less effective, 
since the effective phase following ICB-induced immuno-stimulation requires some time. On 
the other hand, ICB is rarely affected by acquired resistance of cancer cells and is therefore 
capable of inducing long-term disease-free survival for a significant number of patients, 
compared to conventional treatments. By combining ICB to conventional therapies, such as 
radiotherapy, treatment can provide an important short-term efficacy as well as a highly 
increased rate of disease-free long-term survival for patients suffering from HNSCC (Figure 
41). This effect could be further improved, by taking into account the mechanisms underlying 
the combined treatment, including the PD-L1 expression level after X-ray irradiation and 
potential radiation-induced macrophage repolarization.   
 
 During this project, several HNSCC cell lines were used to assess PD-L1 expression at 
the mRNA and protein levels, after X-ray irradiation. The results indicate that while at the 
mRNA level, PD-L1 overexpression is dose- and time-dependent, the most significant increases 
were not necessarily observed at the highest dose of radiation or the latest timing after 
irradiation. Depending on the cell line, specific conditions of PD-L1 overexpression were 
determined. This can be explained by the intrinsic radioresistance of each cancer cell line. Cal27 
cell are radiosensitive, SQD9 cells are radio-resistant and SCC-VII cells present an 
intermediary radioresistance. While Cal27 and SCC-VII cells displayed a significantly 
increased PD-L1 expression 48 h after a 5 Gy irradiation, SQD9 cells only present an increased 
PD-L1 expression 72 h after irradiation, with a maximal increase after a 5 Gy irradiation. Unlike 
SCC-VII cells, Cal27 cells showed no increase in PD-L1 expression 72 h after irradiation. This 
might be due to too important DNA damage and cell function impairment. At protein level, the 
results clearly indicate that PD-L1 expression at the cell membrane gradually increases in a 
dose- and time-dependent manner. Based on these results, we suggest that when using anti- 
PD-1/PD-L1 ICB in combination with radiotherapy, the antibody should not be administrated 
simultaneously with the irradiation but it should be administrated at least 48 h after irradiation 
to actively block PD-L1-mediated T cell inactivation by cancer cells and induce T cell-, NK  
cell-  and complement-mediated cytotoxicity. Further investigations should assess PD-L1 




which, maintaining a constant level of ICB is crucial to optimally promote cancer cell 
eradication by the adaptive and innate immune system.  
 
 Based on the controversial information regarding whether photon and/or proton 
irradiation could both induce macrophage repolarization or if this can only be achieved by 
proton irradiation (Genard et al., 2017; Genard at al., 2018), we decided to also focus our 
attention on the compared immunomodulatory effect of proton vs photon irradiation. This study 
started by assessing PD-L1 expression following proton or photon irradiation. Due to technical 
limitations, currently only results of PD-L1 expression at the mRNA level in SCC-VII cell are 
available. The results show that only X-ray irradiation could induce PD-L1 overexpression. At 
this stage, we do not know, if at the protein level proton irradiation affects PD-L1 expression. 
This preliminary result indicates that the immuno-modulatory effects of proton vs. photon 
irradiation differ one from each other in vitro. To determine how proton irradiation acts 
differently on PD-L1 expression compared to X-ray irradiation, we suggest to start 
investigating the activation of the DDR mediated Stat1/3 – IRF-1 induction of PD-L1 following 
photon and proton irradiation. These experiments are already launched in progress. First results 
will soon be available.  
 
 Recently, Genard and colleagues showed that the impact of both types of radiation on 
macrophage polarization does not seem to be the same. While in vitro results regarding photon 
irradiation-induced macrophage repolarization from different studies are in disagreement 
whether radiation induces macrophage repolarization toward the M1 or M2 phenotype, it seems 
that in vivo X-ray irradiation does induces macrophage polarization towards an iNOS+ M1-like 
phenotype (Klug et al., 2013). This shows the limitations and differences of in vitro TAMs 
models and the difficulty to accurately investigate one same biological process. For this reason, 
in the present study, an in vivo model of HNSCC was set up, to investigate more accurately  
X-ray irradiation-induced TAM repolarization and its impact on PD-1 ICB. This set up aimed 
to create a model of HNSCC, that allows the study of immune cells infiltrating the tumor. Since 
the immune-environment specific to each type of tissue throughout the body is known to have 
an impact on anti-cancer immune response within a specific organ, an orthotopic model would 
be optimal for our study. Although these models are much more reliable for the investigation 
of anti-cancer immune-reactions, we decided to exclude that option for several reasons. First, 
it required advanced skills for the precise injection of cancer cell into the appropriate site in the 
head and neck region, as well as the appropriate skills to precisely resect these tumors. Second, 
the formation of tumors, typically at the base of the tongue, often lead to a high number of 
premature deaths of mice due to cachexia (Lei et al., 2016). Third, for the intended analysis of 
CD8+ TILs and TAMs, a relatively important tumor volume is required (350 mm3), which 
cannot be obtain in the head and neck region of mice. For this same reason, genetically 
engineered mice that spontaneously produce HNC were not considered. We therefore chose a 
synergic subcutaneous model of HNSCC. Different numbers of cells were injected to evaluate 
the tumor development depending on the number of injected cells. We also assessed whether 
250 or 350 mm3 of tumor volume are sufficient for the intended analysis. Histologic analysis 
were performed to characterize the phenotype of cancer cells, tumor vascularization, cancer 




are highly vascularized and infiltrated by immune cells, which spread homogenously 
throughout the tumors. It was shown macroscopically that cancer cells are highly invasive, 
infiltrating nearby muscles and LNs as well as distant LNs after growing approximately 5 
weeks. Cancer cells in the tumor periphery present a mesenchymal-like phenotype similar to 
the phenotype observed in the periphery of distant LNs cancer cells. This leads us to believe 
that cancer cells observed in the periphery of the tumors undergo epithelio-mesenchymal 
transition and invade subsequently distant LNs. No cancer cells infiltration could be observed 
in the spleen. From 350 mm3 big tumors, sufficient TILs and TAMs could be isolated to perform 
the intended flow cytometry analysis after splitting tumor in three sections for, TILs and TAM 
isolation, RNA extraction and histologic analysis. At this stage, based on the histology analysis, 
no significant difference could be observed so far between untreated mice and mice treated by 
X-ray irradiation. It seems that mice treated by X-ray irradiation have an increased number of 
TILs, similarly to what has been described previously after low dose γ–ray irradiation (Klug et 
al., 2013). Immuno-fluorescence labelling and subsequent quantification of CD3+ TILs 
remains to be performed to confirm this observation. Based on the results, we meanwhile 
validated our syngenic model of subcutaneous HNSCC and initiated a second project which 
aimed to investigate the efficiency of a combined treatment of anti-PD-1 ICB and radiotherapy 
as well as the underlying mechanisms. 
 
 During this second project, mice were treated by X-ray irradiation, anti-PD-1 ICB or 
the combined treatment in order to investigate the potential synergic effect regarding CD8+ 
TILs activation and exhaustion levels but also to investigate the impact of potential radiation-
induced TAM repolarization on treatment efficiency. We found that X-ray irradiation induced 
a significantly increased early and late CD8+ T cell activation. The hypothesis was that 
radiation-induced macrophage repolarization from an M2, towards an M1-like phenotype 
induced increased lymphocyte recruitment, lower TILs inactivation and immunosuppression, 
in addition to increased pro-inflammatory cytokine secretion and TIL activation after antigen 
presentation. In order to confirm this hypothesis, TAM polarization needed to be assessed. 
While flow cytometry analysis allows to specifically analyze TAMs independently of other 
myeloid cell such as monocytes DC or neutrophils, with the available equipment only one TAM 
polarization marker could be assessed. MH-CII and CD80 (data not shown), which are 
commonly recommended polarization markers, were both tested during the pilot project to 
determine which one is best suited to distinguish M1 from M2 TAMs. Only using MHC-II 
allowed to clearly differentiate between both polarizations (data not shown). During the main 
in vivo project using this polarization marker, no TAM repolarization from and M2 towards and 
M1-like could be observe. This could mean that X-ray irradiation does not induce TAM 
repolarization and that the increased TILs recruitment and activation is not mediated by TAM 
repolarization. However, the determination of TAM polarization using only one polarization 
marker can be an important bias. It is possible that X-ray irradiation induces TAM 
repolarization towards and M1-like phenotype but that this requires the assessment of several 
polarization markers at the protein and mRNA level. Whole tumor RNA isolations were 
performed assess macrophage polarization markers by RT-qPCR. It should be noted that this 
technique can be biased by all other cells inside the TME. It is however recognized as an 




to accurately evaluate TAM polarization is to isolate TAMs from the tumors and analyze them 
by mass cytometry coupled to subsequent single cell RNA sequencing. This would allow to 
assess the expression of numerous polarization markers at once. This way, TAMs could even 
be subdivided into specific populations of TAMs which might have individual functions on 
immuno-modulation at the TME, for instance CD8+ TILs activation and recruitment. To 
quantify the impact of X-ray irradiation on TAM recruitment in the TME, immune-
histochemistry staining for F4/80+ cell within the tumors is required. The technique is currently 
in development in our lab and results can be expected soon. 
 
 During the main in vivo project, mice treated with an anti-PD-1 ICB showed a 
significantly increased CD8+ TIL activation as well as a shift in TAM polarization from an 
M2-like towards a M1-like phenotype. This ICB thus efficiently blocked the induction of T cell 
inactivation by preventing receptor to ligand interaction. Surprisingly, this anti-PD-1 ICB also 
induced an increase in M1-like macrophage polarization and a decrease of M2-like 
macrophages within the myeloid cell population. Mechanisms underlying this ICB-induced 
macrophage repolarization remain unclear and require further investigation. 
 
 The combined treatment of X-ray irradiation followed by anti-PD-1 ICB administration 
showed only very low efficiency since besides a slight increase in late CD8+ TIL activation 
and small decrease in MHC-IIlow macrophages, no improvement in the anticancer immune 
response could be observed. However, this result would need to be confirmed by a second in 
vivo experiment. Indeed, significant technical problems with X-ray generator caused an 
important delay for the irradiation of mice. This delay could explain an altered immune-
background within the tumor by the time the treatment was administrated and thereby influence 
the results. It should also be mentioned that the treatment efficiency for this project was defined 
as the activation and exhaustion levels of CD8+ T cells. We have no information on the efficacy 
of the combined treatment regarding tumor development and survival of tumor bearing mice. 
Independent experiments would need to be performed to determine if the combined treatment 
has a synergic effect regarding mice survival.  
 
 In order to determine the role of TAMs, independently of their polarization, on the 
efficiency of the combined treatment of anti-PD-1 ICB and X-ray irradiation, a new in vivo 
experiment should be initiated containing the four experimental groups as previously but mice 
would undergo macrophage depletion by clodronate-loaded liposome treatment. This way, the 
impact of the combined treatment on immune cell infiltration and CD8+ TIL activation and 
exhaustion can be evaluated independently of the impact of TAMs on the anti-cancer immune 
response. This would allow a better understanding of the role of TAMs in anti-cancer immunity, 
treatment response and cancer cell resistance. Afterwards, new in vivo experiments could be 
launched using proton or carbon ion irradiation instead of X-ray irradiation to evaluate proton 
vs. carbon- vs. photon-irradiation-induced immuno-modulation, based on the previously used 
criteria, immune infiltration, TAM polarization and T cell activation. Since the efficacy of 
proton and carbon-irradiation with ICBs has never been performed yet, additionally survival 





 In conclusion, this project allowed to elucidate in vitro and in vivo some of the 
radiotherapy-induced immuno-modulatory effects within the tumor microenvironment, that can 
be exploited in clinics for improved anti-cancer therapy, most notably immune checkpoint 




































Brandsma,	 I.,	&	Gent,	D.	C.	 (2012).	Pathway	choice	 in	DNA	double	strand	break	repair:	
observations	of	a	balancing	act.	Genome	Integr,	3(1),	9.	doi:10.1186/2041-9414-3-
9	
Champiat,	 S.,	 Ileana,	 E.,	 et	 al.	 (2014).	 Incorporating	 immune-checkpoint	 inhibitors	 into	
systemic	 therapy	 of	 NSCLC.	 J	 Thorac	 Oncol,	 9(2),	 144-53.	
doi:10.1097/JTO.0000000000000074	
Chen,	 Y.,	 &	 Ahmad,	 S.	 (2012).	 Empirical	 model	 estimation	 of	 relative	 biological	




Deng,	 L.,	 Liang,	 H.,	 et	 al.	 (2014).	 Irradiation	 and	 anti-PD-L1	 treatment	 synergistically	






Carcinoma	 of	 the	 Head	 and	 Neck.	 N	 Engl	 J	 Med,	 375(19),	 1856-1867.	
doi:10.1056/NEJMoa1602252	
Genard,	G.,	 Lucas,	 S.,	 et	 al.	 (2017).	Reprogramming	of	 Tumor-Associated	Macrophages	







future	 considerations.	 J	 Immunother	 Cancer,	 6(1),	 8.	 doi:10.1186/s40425-018-
0316-z	
Green,	 C.	 E.,	 Liu,	 T.,	 et	 al.	 (2009).	 Chemoattractant	 signaling	 between	 tumor	 cells	 and	













Mammalian	cells	more	sensitive	to	proton	versus	photon	 irradiation.	 Int	 J	Radiat	
Oncol	Biol	Phys,	88(1),	175-81.	doi:10.1016/j.ijrobp.2013.09.041	
Hanahan,	 D.,	 &	 Coussens,	 L.	 M.	 (2012).	 Accessories	 to	 the	 crime:	 functions	 of	 cells	
recruited	 to	 the	 tumor	 microenvironment.	 Cancer	 Cell,	 21(3),	 309-22.	
doi:10.1016/j.ccr.2012.02.022	
Hanahan,	D.,	&	Weinberg,	R.	A.	(2000).	The	hallmarks	of	cancer.	Cell,	100(1),	57-70.		
Hanahan,	D.,	&	Weinberg,	R.	A.	 (2011).	Hallmarks	of	 cancer:	 the	next	generation.	Cell,	
144(5),	646-74.	doi:10.1016/j.cell.2011.02.013	
Hargadon,	K.	M.,	Johnson,	C.	E.,	et	al.	(2018).	 Immune	checkpoint	blockade	therapy	for	
cancer:	 An	 overview	 of	 FDA-approved	 immune	 checkpoint	 inhibitors.	 Int	
Immunopharmacol,	62,	29-39.	doi:10.1016/j.intimp.2018.06.001	
Harrington,	 K.	 J.,	 Ferris,	 R.	 L.,	 et	 al.	 (2017).	 Nivolumab	 versus	 standard,	 single-agent	
therapy	of	investigator's	choice	in	recurrent	or	metastatic	squamous	cell	carcinoma	
of	the	head	and	neck	(CheckMate	141):	health-related	quality-of-life	results	from	a	








Klug,	 F.,	 Prakash,	 H.,	 et	 al.	 (2013).	 Low-dose	 irradiation	 programs	 macrophage	




Krysko,	D.	 V.,	Garg,	A.	D.,	 et	 al.	 (2012).	 Immunogenic	 cell	 death	 and	DAMPs	 in	 cancer	
therapy.	Nat	Rev	Cancer,	12(12),	860-75.	doi:10.1038/nrc3380	
















the	 present	 and	 the	 future.	 Semin	 Radiat	 Oncol,	 23(2),	 127-33.	
doi:10.1016/j.semradonc.2012.11.004	
Nirschl,	 C.	 J.,	 &	 Drake,	 C.	 G.	 (2013).	 Molecular	 pathways:	 coexpression	 of	 immune	
checkpoint	 molecules:	 signaling	 pathways	 and	 implications	 for	 cancer	
immunotherapy.	Clin	Cancer	Res,	19(18),	4917-24.	doi:10.1158/1078-0432.CCR-12-
1972	







after	 proton-induced	 DNA	 damage.	 Mutagenesis,	 23(2),	 119-29.	
doi:10.1093/mutage/gem055	
Sato,	H.,	Niimi,	A.,	et	al.	(2017).	DNA	double-strand	break	repair	pathway	regulates	PD-L1	
expression	 in	 cancer	 cells.	 Nat	 Commun,	 8(1),	 1751.	 doi:10.1038/s41467-017-
01883-9	
Schaue,	 D.,	 Ratikan,	 J.	 A.,	 et	 al.	 (2012).	Maximizing	 tumor	 immunity	with	 fractionated	
radiation.	 Int	 J	 Radiat	 Oncol	 Biol	 Phys,	 83(4),	 1306-10.	
doi:10.1016/j.ijrobp.2011.09.049	
Schiller,	K.	C.,	Habl,	G.,	et	al.	(2016).	Protons,	Photons,	and	the	Prostate	-	Is	There	Emerging	
Evidence	 in	 the	 Ongoing	 Discussion	 on	 Particle	 Therapy	 for	 the	 Treatment	 of	
Prostate	Cancer?	Front	Oncol,	6,	8.	doi:10.3389/fonc.2016.00008	
Schreiber,	R.	D.,	Old,	 L.	 J.,	 et	 al.	 (2011).	Cancer	 immunoediting:	 integrating	 immunity's	





and	macrophages	 promote	 lymph	 node	metastasis	 via	 CCR4/CCL22	 in	 head	 and	




















































DAEP  2014   Version  2014/01 
1 
Demande d’autorisation d’essai préliminaire  
utilisant des animaux d’expérience 
 
 
I. Présentation de l’essai préliminaire 
 
TITRE DE L’EXPERIENCE dans laquelle l’essai préliminaire s’inscrit :  
 
Etude de la reprogrammation des macrophages tumoraux par irradiation avec des photons afin 
d’amplifier l’effet d’anticorps ciblant l’immunomodulateur PD-L1 sur des tumeurs murines 
d’origine ORL 
   
Laboratoire : Unité de Recherche en Biologie Cellulaire (URBC)-Narilis- Faculté des Sciences                         
N° d'agrément LA : LA1900053 
 
Directeur : Thierry Arnould  Tel.:  +32 (0)81 72 41 25   Email: thierry.arnould@unamur.be 
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Nombre d’animaux : 
 Nombre d’animaux Espèce et souche  
Du 15/08 au 15/10/2018 27 Mus musculus C3H/HeOuJ 
 
Type d’essai préliminaire : 
 Mise au point d’une technique opératoire 
 Mise au point d’un protocole anesthésique   
 Mise au point d’un protocole analgésique   
 Détermination du niveau de douleur d’une expérience 
 Détermination du dosage d’un produit à tester 
 Mise au point des points limites 
 Autre : Mise au point du volume tumoral nécessaire à l’isolation des TILs et TAMs (Justification de 
l’essai)  
 
Niveau de gravité de l’essai (si connu) : 
 NR : non recovery - sans réveil : sans aucune douleur ou aucun inconfort 
 Léger    
 Modéré   
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II. Justification et description de l’essai préliminaire 
 
Justification de l’essai, du nombre d’animaux et du temps demandé  
 
Nous savons que parmi les nombreux acteurs qui permettent à notre système immunitaire de lutter 
contre les maladies, dont le cancer, les lymphocytes T jouent un rôle primordial. Toutefois, les 
cellules tumorales peuvent échapper au système immunitaire, notamment en exprimant à leur 
surface une protéine appelée PD-L1. PD-L1 va inactiver les lymphocytes T en se liant à des 
récepteurs dont PD-1 présents à la surface des lymphocytes T. Cette liaison entre PD-L1 et ses 
récepteurs constitue une cible thérapeutique intéressante pour l’immuno-oncologie. En effet, le 
blocage de la protéine PD-L1 peut empêcher les cellules cancéreuses d'inactiver les lymphocytes T 
et ainsi permettre aux lymphocytes T cytotoxiques (CD8+) de retrouver leur rôle dans la destruction 
des cellules cancéreuses. Récemment, il a été démontré que l’expression de l’immuno-modulateur 
PD-L1 dans les cellules tumorales pouvait augmenter suite à une irradiation par photons (Deng et 
al, 2014). In vitro, nos résultats  préliminaires sur des lignées tumorales humaines d’origine ORL 
ont d’ailleurs permis de mettre en évidence une variation de l’expression de PD-L1 en fonction de 
la dose de rayons X et du temps post-irradiation (Christoph Schifflers, master 1 BBMC, mini-
mémoire, juin 2018). L’irradiation restant un traitement standard dans de nombreux cancers, la 
combinaison d’un anticorps anti-PD-L1 avec des rayons X semble prometteuse, et son utilisation 
dans des conditions optimales favoriserait une efficacité thérapeutique maximale. Cependant, les 
mécanismes sous-jacents à l’efficacité de ce traitement combiné restent peu connus.  
 
Les macrophages associés aux tumeurs (TAMs) représentent une majorité des cellules immunitaires 
présentes dans le micro-environnement tumoral. Ces TAMs présentent des phénotypes différents, 
variant entre un phénotype de type M1 (pro-inflammatoire/anti-tumoral) et un phénotype de type 
M2 (anti-inflammatoire/pro-tumoral). Une tumeur à un stade débutant sera principalement associée 
à des TAMs de type M1, c’est-à-dire de macrophages anti-tumoraux. A un stade tumoral plus 
avancé, le micro-environnement sera principalement constitué de TAMs de type M2 pro-tumoraux. 
Cependant, ces phénotypes M1 et M2 sont modulables en fonction de différents facteurs 
environnants. Il a notamment été démontré que l’irradiation par photons et protons pouvait 
permettre de repolariser les macrophages M2 pro-tumoraux vers un phénotype M1 anti-tumoral 
(Genard et al, 2017).  
 
Notre hypothèse de travail est donc que l’irradiation par photons en amplifiant l’expression de PD-
L1 permet d’augmenter l’effet d’une immunothérapie par un anticorps anti-PD-L1 et ce, via la 
désinhibition des lymphocytes cytotoxiques infiltrant la tumeur (TILs), mais également via la 
repolarisation des macrophages associés aux tumeurs (TAMs) vers un phénotype de type anti-
tumoral. 
 
L'étude in vitro nous a permis d’étudier la plasticité des macrophages humains, polarisés à partir de 
monocytes humains, les THP-1, après l’irradiation par photons ainsi que les mécanismes impliqués 
dans cette éventuelle repolarisation des macrophages (résultats repris dans la thèse de Géraldine 
Genard, en URBC, défendue en mai 2018). Elle nous a permis également d’étudier l’effet 
immunomodulateur des photons sur des cellules cancéreuses d’origine ORL ainsi que les doses et 
timing post-irradiation permettant une efficacité thérapeutique maximale de l’anticorps anti-PD-L1.  
 
L’expérimentation animale nous permettra quant à elle, d’étudier dans un modèle plus complexe 
l’effet de l’irradiation par photons sur le phénotype des TAMs et des TILs. Ces informations sont 
impossibles à obtenir sur un modèle in vitro puisque les TAMs et les TILs sont fondamentalement 
différents des macrophages différenciés expérimentalement à partir de monocytes et des 
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Afin de pouvoir investiguer la population immunitaire dans l’environnement tumoral, un modèle 
syngénique murin sera utilisé (Smith et al. 2006). Pour cela, une lignée cellulaire tumorale d’origine 
ORL, la lignée SCC-VII, développée spontanément chez la souris C3H, sera injectée en sous-
cutanée afin d’induire progressivement une tumeur. Celle-ci a déjà été étudiée et décrite dans la 
littérature en association à une immunothérapie (Khurana et al. 2001). De plus, la lignée tumorale 
SCC-VII est agressive et peu immunogène. Elle représente donc un modèle idéal pour étudier la 
réponse tumorale spécifique des cellules T. Ce modèle nous permettra également d’analyser 
l’efficacité du traitement combiné sur le système immunitaire. Nous avons choisi d’utiliser la souris 
C3H/HeOuJ comme modèle syngénique car celle-ci est disponible chez Charles River et a déjà été 
étudiée in vivo avec la même lignée tumorale (Duarte et al. 2012).  
 
Cette étude in vivo sur un modèle syngénique nous permettra d’isoler les lymphocytes T CD8+ 
infiltrant la tumeur (TILs) afin d’étudier l’activation par analyses en cytométrie en flux 
(Ahmadzadeh et al, 2009) ainsi que le phénotype des macrophages associés aux tumeurs et ce, après 
traitement par irradiation et/ou des anticorps anti-PD-L1. De plus, le modèle syngénique nous 
permettra également de faire des analyses histologiques, notamment pour étudier l’impact à court 
terme du traitement par irradiation et/ou des anticorps anti-PD-L1 sur les TAMs et les TILs mais 
aussi d’évaluer des éventuelles altérations au niveau des organes lymphoïdes drainant la tumeur.  
 
Cette étude n’ayant jamais été réalisée, ce projet préliminaire a pour but de déterminer les 
conditions expérimentales optimales pour le projet principal. Pour ceci, le projet préliminaire devra 
déterminer 2 paramètres importants avant de commencer le projet principal :  
 
• Le nombre de cellules murines cancéreuses d’origine ORL, les SCC-VII, à injecter par 
souris (250 000, 500 000 ou 1 000 000 cellules) ; le but étant de déterminer un temps de 
croissance tumoral suffisant que pour obtenir un infiltrat immunitaire péri-tumoral 
analysable. En effet, si la croissance tumorale est trop rapide, la réponse immunitaire risque 
d’être pauvre et la tumeur risque de contenir plus de zones de nécrose.  
• Un volume  tumoral suffisant que pour réaliser les analyses biologiques prévues1, 
considérant que la tumeur sera scindée en 2 parties (volume tumoral total : 250  mm3 ou 350 
mm3, déterminé après discussion avec Kathleen Schmit sur base de son projet 
DAEP16273AR, cfr images en annexe) ; nous souhaitons une taille tumorale suffisante pour 
faire nos analyses mais sans atteindre un volume trop important (> 350 mm3) qui pourrait 
contenir plus de plages de nécrose et pourraient impacter sur le bien-être de la souris. 
 
Considérant ces 2 paramètres à déterminer, nous souhaiterions utiliser 3 souris par groupe 
expérimental, afin de nous assurer de la faisabilité de nos expériences.  
L’utilisation de 3 souris nous permettra également de comparer en histologie une tumeur analysée 
dans son entièreté par rapport à une tumeur scindée en deux moitiés, l’une pour comparer la 
répartition et la proportion des différentes populations cellulaires grâce à des coupes histologiques, 
et l’autre moitié pour permettre l’obtention en nombre suffisant de TILs et de TAMs pour des 
analyses par cytométrie en flux. 
 
Le nombre de souris nécessaire à ce projet préliminaire est donc égale à :  
 
Nombre de souris (3) par groupe expérimental (6), additionné de 3 souris contrôle (non irradiées) 
dans chaque groupe d’injection de cellules cancéreuses (3). 
        
                                                
1 Isolation de cellules spécifiques (TILs et TAMs) et analyses par cytométrie en flux ; Analyse histologique des tumeurs 
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 Donc :                                                        		27 souris s 
 
De plus, cette étude préliminaire nous permettra de mettre au point les conditions d’irradiation, 
notamment l’utilisation d’une surface plombée, pour limiter l’irradiation au site d’injection des 
cellules cancéreuses (voir description de l’essai) mais également les conditions pour maintenir un 
confort optimal pour les souris avant, pendant et après l’irradiation.  
 
Nous essayerons un temps de 8 semaines pour réaliser l’essai préliminaire. 27 souris femelles seront 
achetées à 5-6 semaines d’âge et resteront en acclimatation durant 1 à 2 semaines avant d’être 
injectées de 250 000, 500 000 ou 1 000 000 de cellules cancéreuses. L’irradiation aura lieu lorsque 
la tumeur aura atteint le volume attendu (250 mm3 ou 350 mm3), environ 2 à 4 semaines après 
l’injection. L’euthanasie aura lieu 72 h après l’irradiation et/ou l’injection de l’anticorps anti-PD-L1 
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Description de l’essai  
 
• Les souris (femelles) seront achetées à l’âge de 5-6 semaines et hébergées à l’animalerie 
centralisée de l’extension biologie de l’UNamur (L1900631).  
• Après 1-2 semaines d’acclimatation, les souris seront individuellement anesthésiées à 
l’isoflurane (3-4% avec un débit d’oxygène de 0,8-1,5 L/min) en utilisant la table d’anesthésie 
disponible à l’animalerie centrale. Sous anesthésie, elles recevront alors l’injection dans 150 µl 
de PBS de 250 000, 500 000 ou 1 000 000 de cellules cancéreuses SCC-VII en sous-cutané au 
niveau du flanc droit et ce, afin d’éviter d’irradier la rate (organe lymphoïde secondaire) 
présente au niveau du flanc gauche. Les souris seront ensuite placées sous une lampe chauffante 
afin de maintenir leur température corporelle jusqu’à leur réveil. A noter que lors de l’anesthésie 
de la première souris, une plaque en plomb (15 cm x 10 cm x 0,5 - 1 cm) sera maintenue 1 cm 
au-dessus de la souris et un trou d’environ 1 cm de diamètre sera coupé dans la plaque juste au 
niveau de la tumeur. Cette plaque servira de moyen de radioprotection lors de l’irradiation par 
rayons X pour limiter l’exposition uniquement au site d’injection des cellules cancéreuses.  
• Une fois réveillées, une administration d’analgésique sera réalisée par injection de 
buprénorphine (0,05 mg/kg, en sous-cutané - Flecknell 2018), en cas de signes de douleur. Une 
fois la taille tumorale atteinte selon le groupe expérimental défini, environ 2 à 4 semaines après 
l’injection, les souris seront irradiées. A ce moment-là, les souris, par groupe de 3, seront 
anesthésiées via une injection intra-péritonéale de Kétamine et de Xylazine (100 mg/kg et 10 
mg/kg, en intra-péritonéal (suivant le protocole validé ANIM PO 0007 déposé sur la plate-forme 
SVTA) et transportées au laboratoire d’analyses par réactions nucléaires (LARN, Prof. Stéphane 
Lucas LA 1900053) dans une cage de transport, emballée dans un sac poubelle opaque afin de 
ne pas être vues par des personnes non-impliquées dans ce projet. Au LARN, elles seront 
irradiées individuellement par rayons X avec une dose unique de 5 ou 10 Gy, suivant les 
conditions préalablement déterminées in vitro (Christoph Schifflers, master 1 BBMC, mémoire, 
2018). Pour cela, la souris sera placée dans le générateur (X-RAD 225XL/Xli X-ray generator 
(PXI Precision X-ray)), sur un gel préchauffé à 37°C pour éviter l’hypothermie. Un portoir, sur 
lequel la plaque de plomb préalablement préparée sera déposée, sera placé au-dessus de la 
souris, sans la toucher. Après l’irradiation, les souris seront replacées dans leur cage également 
munie d’un gel préchauffé et ramenées à l’animalerie centrale.  
• Les souris seront euthanasiées 72 heures après l’irradiation. Pour ceci, une anesthésie générale 
via une injection intra-péritonéale de Kétamine et de Xylazine (100 mg/kg et 10 mg/kg, I.P.) 
(suivant le protocole validé ANIM PO 0007 déposé sur la plate-forme SVTA) sera réalisée à 
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laboratoire de physiologie générale en URPhyM (LA 1900055), où une ponction intra-cardiaque 
sera réalisée pour prélever un volume sanguin maximal, qui servira à l’isolation des monocytes 
périphériques circulants. La ponction intra-cardiaque sera suivie d’une dislocation cervicale. 
Post-mortem, différents tissus seront prélevés : la tumeur, ainsi que divers organes lymphoïdes 
(analyses histologiques) tels que la rate, l’intestin (la jonction iléo-coecale), des ganglions 
lymphatiques et si possible le thymus. Afin d’isoler différentes populations cellulaires à partir 
des tumeurs (TILs et TAMs), celles-ci doivent être dissociées et les cellules isolées au plus vite 
après l’euthanasie des souris et ce en utilisant un gentleMACS dissociateur. Considérant que la 
dissociation tumorale et l’isolation des cellules doivent être effectuées le plus rapidement 
possible et nécessitent un l’équipement uniquement disponible au laboratoire de physiologie 
générale, les euthanasies doivent avoir lieu au laboratoire de physiologie générale. L’anesthésie 
générale (Kétamine/Xylazine) sera cependant réalisée à l’animalerie centrale ce qui permet 
d’éviter le stress associé au transport que les souris subiraient autrement. 
 
Au cours de l’expérimentation animale, le bien-être sera évalué au quotidien en réalisant un examen 
général de chaque animal et en regardant sa réaction à divers stimuli tels que la lumière ou le bruit. 
De plus, l’état de la cage sera vérifié : les niveaux d’eau et de nourriture ingérés seront analysés et il 
y aura un examen macroscopique des selles. Il sera impératif que la présence de la tumeur n’altère 
en rien les comportements physiologiques de l’animal. Un tableau de score est associé pour cette 




Souche + sexe: 
Age au moment de l'injection: 
Poids au moment de l'injection: 
Niveau de douleur: 
  
 
Nom de l'expérimentateur: 
 
 
  score date date date date date date 
Paramètres étudiés Age        
 Poids        
Examen général         
Perte de poids 
 (par rapport au poids total de souris du même âge) 
0 % 0       
5 % 1       
10 % 2       
15 % 4       
20 % 6       
Apparence/couleur 
Normal 0       
Abdomen bleu 1       
Extrémités pâles 2       
Température en surface 
Chaud 0       
Indécis 1       
Froid 2       
Reflexes/réponse au toucher 
+++ 0       
++ 1       
+ 2       
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Comportement dans sa cage 
Normal 0       
Apathie 1       
Léthargie 1       
Rigidité 2       
Léchage 
++ 1       
+ 0       
- 1       
Comportement alimentaire 
Mange ++, boit ++ 0       
Mange +, boit + 1       
Mange -, boit - 2       
Mange --, boit -- 3       
Tremblement - 0       + 1       
Posture voutée - 0       + 1       
Déshydratation 
- 0       
+ 1       
++ 2       
Vomissement 
- 0       
+ 1       
++ 2       
Excréments Normaux 0       Diarrhée 1       
Respiration Normale 0       Difficile 1       
Toux Non 0       Oui 1       
Examen lié à l'expérience         
Infection de plaie 
(post-injection) 
Aucune 0       
Tissu de granulation 
avec rougeur 2 
      
Inflammation avec 
exsudat 4 
      
Ulcération 6       
Croissance de la tumeur interférant 
avec les fonctions vitales  
Non  0       
Oui 6       
 Total        
 
Points limites mis en place dans cet essai qui engendrera une euthanasie de l’animal :  
- Volume tumoral insuffisant (inférieur au volume tumoral attendu en fonction du groupe 
expérimental) à 4 semaines après l’injection des cellules cancéreuses   
- Perte de poids excédant 20 % du poids total par rapport au poids total de souris du même 
âge 
- Croissance de la tumeur interférant avec les fonctions vitales 
- Ulcération à l’endroit de la tumeur 
- Un score ≥ 6 
 
Devenir des animaux en fin d’essai  
 euthanasie 
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III. Décision de la commission d’éthique 
 
N° d’enregistrement : UN   AR 18/326 
 
Date de la réception de la demande : 19/06/18 
 
Date de l’avis de la commission : 10/08/16 
 
 Approbation par la commission d’éthique  
 
 Refus   
 
 
IV. Déclaration du Maître d’expérience et du Directeur du laboratoire 
 
Cette signature suppose que le maître d’expérience et le directeur du laboratoire reconnaissent leur 
pleine responsabilité et leur accord avec les procédures décrites ci-dessus. 
Les signataires en signant ce document : 
- s’engagent à respecter toutes les modalités décrites dans ce document; 
- acceptent de soumettre une adaptation  au dossier pour analyse à la commission d’éthique si  
- confirment que les personnes impliquées dans cette étude possèdent la formation adéquate 








Volume tumoral de 200 à 300 mm3 Volume tumoral de 100 à 200 mm3 
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+Projet destiné à l’évaluation éthique  
des expériences sur animaux 
 
 
I. Présentation de l’expérience  
 
TITRE DE L’EXPERIENCE :  
Etude de la reprogrammation des macrophages tumoraux par irradiation avec des photons afin 
d’amplifier l’effet d’anticorps ciblant l’immunomodulateur PD-L1 sur des tumeurs murines d’origine 
ORL 
 
Nom du Maître d’expérience : Longton Eléonore        
 
Unité de Recherche en Biologie Cellulaire (URBC)-Narilis- Faculté des Sciences N° Agrément : LA1900053 
 
 Nouveau projet  
 Renouvellement d'un projet en fin de validité 
 Adaptation d'un projet en cours 
 
Durée estimée de l’expérience :  4 mois 
 
Nombre d’animaux : 
 Nombre d’animaux Espèce et lignée 
Du 15/08/18 au 15/12/2018 40 Mus musculus C3H/HeOuJ 
 
 
Domaine du projet : 
 Recherche fondamentale 
 Recherche translationnelle ou appliquée  
 Test réglementaire 
 Production ou service de routine  
 Protection de l'environnement 
 Conservation des espèces 
 Enquête médicolégale 
 Enseignement supérieur ou formation 
 Maintien de colonies d'animaux génétiquement modifiés 
  Autre : ……………………………………………………….  
 
 
Niveau de gravité du protocole : 
 NR : non recovery - sans réveil : projet sans aucune douleur ou aucun inconfort 
 
 Gravité légère    
 Gravité modérée 
 Gravité sévère  
 
 
N° d’enregistrement : UN  AR 18/326 
 
Date de la réception de la demande : 19/06/2018 
 
Date de l’avis de la CEEXPANI : 10/08/2018 
 
 Approbation par la CEEXPANI (2 ans maximum) : du    15/08/18            au 31/12/19 
 Refus   
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II. Commentaires de la Commission d’éthique en expérimentation animale 
 
 
REMARQUES / QUESTIONS / SUGGESTIONS de la CEEXPANI qui a examiné la demande en 
date du 26/06/2018. 
 
RÉPONDRE AUX REMARQUES DANS LE TEXTE  
 
SUITE À L’ESSAI PILOTE : REVOIR SI NÉCESSAIRE LE NIVEAU DE SÉVÉRITÉ AU MOINS 
AU NIVEAU DES STATS (SEVERITÉ RÉELLE) 
 
VOIR SI LES RÉSULTATS OBTENUS PENDANT LA PHASE PILOTE PEUVENT ÊTRE 
UTILISÉS DANS LES RÉSULTATS FINAUX  
 
 







CONCLUSIONS :                                                
 
 FAVORABLE SANS CONDITION 
 

























Nous savons que parmi les nombreux acteurs qui permettent à notre système immunitaire de lutter 
contre les maladies, dont le cancer, les lymphocytes T jouent un rôle primordial. Toutefois, les cellules 
tumorales peuvent échapper au système immunitaire, notamment en exprimant à leur surface une 
protéine appelée PD-L1. PD-L1 va inactiver les lymphocytes T en se liant à des récepteurs dont PD-1 
présents à la surface des lymphocytes T. Cette liaison entre PD-L1 et ses récepteurs constitue une cible 
thérapeutique intéressante pour l’immuno-oncologie. En effet, le blocage de la protéine PD-L1 peut 
empêcher les cellules cancéreuses d'inactiver les lymphocytes T et ainsi permettre aux lymphocytes T 
cytotoxiques (CD8+) de retrouver leur rôle dans la destruction des cellules cancéreuses. Récemment, il 
a été démontré que l’expression de l’immuno-modulateur PD-L1 dans les cellules tumorales pouvait 
augmenter suite à une irradiation par photons (Deng et al, 2014). In vitro, nos résultats  préliminaires 
sur des lignées tumorales humaines d’origine ORL ont d’ailleurs permis de mettre en évidence une 
variation de l’expression de PD-L1 en fonction de la dose de rayons X et du temps post-irradiation 
(Christoph Schifflers, master 1 BBMC, mini-mémoire, juin 2018). L’irradiation restant un traitement 
standard dans de nombreux cancers, la combinaison d’un anticorps anti-PD-L1 avec des rayons X 
semble prometteuse, et son utilisation dans des conditions optimales favoriserait une efficacité 
thérapeutique maximale. Cependant, les mécanismes sous-jacents à l’efficacité de ce traitement 
combiné restent peu connus.  
 
Les macrophages associés aux tumeurs (TAMs) représentent une majorité des cellules immunitaires 
présentes dans le micro-environnement tumoral. Ces TAMs présentent des phénotypes différents, 
variant entre un phénotype de type M1 (pro-inflammatoire/anti-tumoral) et un phénotype de type M2 
(anti-inflammatoire/pro-tumoral). Une tumeur à un stade débutant sera principalement associée à des 
TAMs de type M1, c’est-à-dire de macrophages anti-tumoraux. A un stade tumoral plus avancé, le 
micro-environnement sera principalement constitué de TAMs de type M2 pro-tumoraux. Cependant, 
ces phénotypes M1 et M2 sont modulables en fonction de différents facteurs environnants. Il a 
notamment été démontré que l’irradiation par photons et protons pouvait permettre de repolariser les 
macrophages M2 pro-tumoraux vers un phénotype M1 anti-tumoral (Genard et al, 2017).  
 
Notre hypothèse de travail est donc que l’irradiation par photons en amplifiant l’expression de PD-L1 
permet d’augmenter l’effet d’une immunothérapie par un anticorps anti-PD-L1 et ce, via la 
désinhibition des lymphocytes cytotoxiques infiltrant la tumeur (TILs), mais également via la 
repolarisation des macrophages associés aux tumeurs (TAMs) vers un phénotype de type anti-tumoral. 
 
Cette étude in vivo sur un modèle syngénique nous permettra d’isoler les lymphocytes T CD8+ 
infiltrant la tumeur (TILs) afin d’étudier l’activation des lymphocytes par analyses en cytométrie en 
flux (Ahmadzadeh et al, 2009) ainsi que le phénotype des macrophages associés aux tumeurs et ce, 
après traitement par irradiation et/ou anticorps anti-PD-L1. De plus, le modèle syngénique nous 
permettra également de faire des analyses histologiques, notamment pour étudier l’impact à court 
terme du traitement par irradiation et/ou anticorps anti-PD-L1 sur les TAMs et les TILs mais aussi 
d’évaluer des éventuelles altérations au niveau des organes lymphoïdes. Pour cela, l’expérimentation 
in vivo préliminaire nous a permis de déterminer le nombre de cellules cancéreuses à injecter et la 
taille tumorale optimale pour isoler suffisamment de cellules du micro-environnement tumoral. 
 
Veuillez en quelques mots présenter la question scientifique et la démarche expérimentale utilisée ? 
Structurez la réponse en 3 points EN Y AJOUTANT DES REFERENCES SCIENTIFIQUES : 
1. résumer les connaissances actuelles disponibles dans la littérature (= état des lieux) 
2. articuler la question posée par rapport à ce contexte  
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Deng, L., Liang, H., et al. (2014). Irradiation and anti-PD-L1 treatment synergistically promote 
antitumor immunity in mice. J Clin Invest, 124(2), 687-95. doi:10.1172/JCI67313 
 
Ahmadzadeh, M., Johnson, L. A., et al. (2009). Tumor antigen-specific CD8 T cells infiltrating the 
tumor express high levels of PD-1 and are functionally impaired. Blood, 114(8), 1537-44. 
doi:10.1182/blood-2008-12-195792 
 
Genard, G., Lucas, S., et al. (2017). Reprogramming of Tumor-Associated Macrophages with 




IV. Justification du nouveau projet / du renouvellement / de l’adaptation 
 
A. Justification de l’expérience ou de son renouvellement  
 
  
  Cette étude n’a jamais été réalisée 
  Cette étude fait suite aux autres études sur le sujet (suite du projet) 
  Les études antérieures furent non concluantes 
  Bien que semblable à d’autres expériences, cette étude augmente le niveau de connaissance à 
son sujet  




















Veuillez cocher les caractéristiques les plus en relation avec l’étude envisagée en ce qui concerne son 
caractère répétitif éventuel. 
Lors d’une demande de renouvellement, justifiez celle-ci en remplissant le document 
d’évaluation rétrospective de la phase précédente du projet. 
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B. Justification de l’utilisation d’animaux et absence de méthode alternative 
 
1. Pour l'expérience envisagée, existe-t-il une méthode alternative (qui n'utilise pas d'animaux) dont 
la fiabilité est au moins équivalente ? 
 
  Oui  Non  
  
Notre hypothèse de travail est que l’irradiation par photons en amplifiant l’expression de PD-L1 
permet d’augmenter l’effet d’une immunothérapie par un anticorps anti-PD-L1 et ce, via la 
désinhibition des lymphocytes cytotoxiques infiltrant la tumeur (TILs), mais également via la 
repolarisation des macrophages associés aux tumeurs (TAMs) vers un phénotype de type anti-tumoral. 
L'étude in vitro nous permettra d’étudier la plasticité des macrophages après l’irradiation par photons 
ainsi que les mécanismes impliqués dans cette éventuelle repolarisation macrophagiques. Elle nous 
permettra également d’étudier l’effet immunomodulateur des photons sur des cellules cancéreuses 
d’origine ORL ainsi que les doses et timing post-irradiation permettant une efficacité thérapeutique 
maximale de l’anticorps anti-PD-L1.  
 
L’expérimentation animale nous permettra quant à elle, d’étudier dans un modèle plus complexe l’effet 
de l’irradiation par photons sur le phénotype des TAMs et des TILs. Ces informations sont impossibles 
à obtenir sur un modèle in vitro puisque les TAMs et les TILs sont fondamentalement différents des 
macrophages différenciés expérimentalement à partir de monocytes et des lymphocytes circulants qui 
ne sont pas antigène spécifique. De plus, le microenvironnement tumoral ainsi que les cellules 
cancéreuses ont des effets multiples et encore peu connus sur les autres cellules au niveau de la tumeur 
qui ne peuvent pas être simulés in vitro. Cette étude in vivo permettra d’isoler des cellules d’intérêt au 
niveau de la tumeur et de son micro-environnement.  
 
 
2. Justifiez le choix du modèle animal ? Donnez des références scientifiques. 
 
Afin de pouvoir investiguer la population immunitaire dans l’environnement tumoral, un modèle 
syngénique murin sera utilisé (Smith et al. 2006). Pour cela, une lignée cellulaire tumorale d’origine 
ORL, la lignée SCC-VII, développée spontanément chez la souris C3H, sera injectée en sous-cutanée 
afin d’induire progressivement une tumeur. Celle-ci a déjà été étudiée et décrite dans  la littérature en 
association à une immunothérapie (Khurana et al. 2001). De plus, la lignée tumorale SCC VII est 
agressive et peu immunogène. Elle représente donc un modèle idéal pour étudier la réponse tumorale 
spécifique des cellules T. Nous avons choisi d’utiliser la souris C3H/HeOuJ comme modèle 
syngénique car celle-ci est disponible chez Charles River et a déjà été étudiée in vivo avec la même 
lignée tumorale (Duarte et al. 2012).  
 
Smith, L. P. and G. R. Thomas (2006). "Animal models for the study of squamous cell carcinoma of the 
upper aerodigestive tract: a historical perspective with review of their utility and limitations. Part A. 
Chemically-induced de novo cancer, syngeneic animal models of HNSCC, animal models of 
transplanted xenogeneic human tumors." Int J Cancer 118(9): 2111-2122. 
 
Khurana, D., et al. (2001). "Characterization of a spontaneously arising murine squamous cell 
carcinoma (SCC VII) as a prerequisite for head and neck cancer immunotherapy." Head Neck 23(10): 
899-906. 
 
Duarte, S., et al. (2012). "Isolation of head and neck squamous carcinoma cancer stem-like cells in a 
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V. Informations  
 
A. Laboratoire et personnel 
 
Laboratoire :   
Unité de Recherche en Biologie Cellulaire (URBC)-Narilis- Faculté des Sciences                          
 
N° d'agrément :  
LA1900053 
 
Directeur de l’agrément :  
Thierry Arnould      Tel.:  +32 (0)81 72 41 25   Email: thierry.arnould@unamur.be 
 
 
Personnel impliqué dans le laboratoire d'accueil (maîtres d'expérience et bio-techniciens, à 







Tel ou E-mail Formation 
réglementaire (date + 
lieu) 
Thierry Arnould   
porte parole  
 thierry.arnould@unamur.be  2007, ULg 
Carine Michiels   carine.michiels@unamur.be  Acceptée de facto, 
2005  
Eléonore Longton   elelongton@hotmail.com  Janvier 2017, 
UNamur 
Christoph Schifflers   christoph.schifflers@studen
t.unamur.be 
 Mai 2018, 
UNamur  





 2011, UNamur  
 
Autre laboratoire où les expériences (ou parties) sont réalisées  
 
1) Local d’expérimentation (irradiation) 19A situé au LARN (laboratoire d’analyses de 
réactions nucléaires), bâtiment des sciences 
                  LA : 1900053 (extension d’agrément de l’URBC) 
                  Personne de contact : Stéphane Lucas (LARN), Thierry Arnould (URBC) 
 
Approbation de la Commission d’éthique qui supervise ce laboratoire :  Oui  Non 
N° de projet :  Validité : du  .. /../.. au ../../.. 
 
2) Laboratoire de Physiologie générale situé en URPhyM (euthanasie des souris et analyses 
histologiques) 
LA 1900055 
Personne de contact : Nathalie Caron, Tél : +32 (0)81 72 43 30,  
Email: nathalie.caron@unamur.be 
 
Approbation de la Commission d’éthique qui supervise ce laboratoire :  Oui  Non 












 Espèce animale Lignée  Fournisseur    
(+numéro d’agrément) 
Sexe Age/Poids 
Exp 1 Mus musculus  C3H/HeOuJ Charles River, 
L’arbresle, France 
Femelle 5 à 6 semaines 
15 à 20 g 
Exp 2 Mus musculus  C3H/HeOuJ Charles River, 
L’arbresle, France 
Femelle 5 à 6 semaines 
15 à 20 g 
Exp 3 Mus musculus  C3H/HeOuJ Charles River, 
L’arbresle, France 
Femelle 5 à 6 semaines 
15 à 20 g 
Exp 4 Mus musculus  C3H/HeOuJ Charles River, 
L’arbresle, France 
Femelle 5 à 6 semaines 
15 à 20 g 
 
Des animaux génétiquement modifiés seront-ils utilisés dans cette expérience ?      oui   non 
Des animaux présentant un phénotype douloureux seront-ils utilisés dans cette expérience ?     
                 oui   non 
Des animaux d’un précédent projet sont-ils utilisés ?                                  oui   non 
 
Nombre d’animaux : 
 Exp 1  Exp 2 Exp 3  Exp 4  
Du 01/09/2018 au 01/01/2019   10 10 10 10 
 
Calcul statistique : 
 
Considérant que l’étude de l’activation des lymphocytes CD8+infiltrant la tumeur en réponse à un 
traitement par rayons X et/ou anticorps anti-PD-L1, n’a jamais été réalisée, il n’est pas possible sur 
base de la littérature, ni sur bases de résultats expérimentaux in vitro, de déterminer le seuil à partir 
duquel une différence d’activation des lymphocytes peut être considérée comme significative. Pour 
cette même raison, la déviation standard nécessaire au calcul du nombre de souris ne peut pas être 
anticipée (sous réserve des résultats obtenus grâce au projet in vivo préliminaire).  
 
Cependant, nous pouvons nous baser sur une récente étude in vivo utilisant un traitement combiné 
semblable par photons et injection d’anticorps anti-PD-L1, ayant obtenu des résultats significatifs en 
utilisant un total de 8 souris par groupe expérimental (Simon J. Dovedi and al. Acquired Resistance to 
Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade. Cancer Research. Oct 
2014). Considérant le risque associé  aux anesthésies, ainsi qu’à l’injection des cellules cancéreuses et 
la croissance tumorale résultante, 2 souris supplémentaires sont rajoutées à chaque groupe 
expérimental afin d’assurer le nombre minimal de souris nécessaires à 8 en fin de l’expérience. Nous 
utiliserons donc 10 souris par groupe expérimental. 
 
Méthode d’identification des animaux : 
Marquage des souris par marqueur au niveau de la queue et étiquettes annotées sur les cages. 
 
Lieu d’hébergement des animaux (numéro de local/nom de l’animalerie) :  
Animalerie centralisée de l’extension biologie L1900631 
 
Lieu où a lieu l’expérimentation (numéro de local/ nom du laboratoire) :  
• L1900631 Animalerie centralisée de l’extension biologie 
• URBC 
• LARN 






ETHICFORM2018   18/326 AR souris photons   Version  2018/01 
8 
Devenir des animaux en fin d’étude  
 euthanasie 
 possibilité de réutilisation (dans ce cas, prouvez la non-incidence sur des études ultérieures) : 
 
 
Evaluation du bien-être : 
Niveau(x) de Gravité (expérience 1, 2, …) :   NR     léger    modéré     sévère    
 
Justifiez votre choix :   
L’injection sous-cutanée de cellules cancéreuses va engendrer la formation d’une masse tumorale 
pouvant impacter l’état de santé général et le bien-être de la souris. L’irradiation sera limité au niveau 
de la tumeur. Pour cela, le reste de la souris sera protégé par une plaque en plomb absorbant 99% de la 
radiation (0,5 à 1 cm d’épaisseur). L’anticorps sera injecté en i.p. en une seule injection.  
 
Prévention de la douleur ?      oui   non 
Si oui, veuillez préciser les méthodes dans le projet expérimental 
 
Si non : pourquoi ? 
Les cellules cancéreuses ne prolifèreront pas suffisamment longtemps pour engendrer des perturbation 
physiologiques importants. En plus, 3 jours après l’irradiation des tumeurs et/ou l’injection de l’anti-
PD-L1, les souris seront euthanasiées.   
 
Cependant, en cas de signes de douleur (modification du comportement, de la posture et de 
l’apparence de la souris- Miller 2011), une administration d’analgésique sera réalisée par injection de 
buprénorphine (0,05 mg/kg, en sous-cutané – Flecknell 2018). L’analgésie sera bien sûre adaptée en 
fonction de la douleur de l’animal et des données du projet préliminaire.  
 
Type d’hébergement et nombre d’animaux par cage (en cas d’hébergement individuel justifiez) :  
Les animaux seront hébergés dans des cages Tecniplast GM500 (500 cm
2
). Cinq souris, uniquement 
du même sexe et du même groupe expérimental, pourront être hébergées dans une cage.  
Quels sont les efforts pour améliorer le bien-être au quotidien ? Quel(s) type(s) d’enrichissement 
utilisez-vous ?  
Les cages sont munies d’une litière en sciure, changée régulièrement.  
Afin d’enrichir le milieu, des tubes en carton et en PVC sont placés dans la cage, ainsi que des 
copeaux de bois, permettant aux souris de se créer un nid. Adaptation du confort en fonction du 
comportement des souris.  
Les cages sont munies d’un biberon d’eau qui sera remplacée tous les jours et les souris sont nourries 
ad libitum avec de la nourriture en pellets.  
Les conditions de température sont maintenues constantes (22°C +- 2°C) ainsi que les conditions de 
luminosité (12h par jour). 
 
Evaluation du bien-être au quotidien : 
- critères d’évaluation (grille/score) ? 
 
Le bien-être sera évalué en réalisant un examen général de l’animal et en regardant sa réaction à divers 
stimuli tels que la lumière ou le bruit. De plus, l’état de la cage sera vérifié. Il sera impératif que la 
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Animal ID: 
Souche + sexe: 
Age au moment de l'injection: 
Poids au moment de l'injection: 
Niveau de douleur: 
  
Nom de l'expérimentateur: 
  score date date date date date date 
Paramètres étudiés Age        
 Poids        
Examen général         
Perte de poids 
 (par rapport au poids total de souris du même âge) 
0 % 0       
5 % 1       
10 % 2       
15 % 4       
20 % 6       
Apparence/couleur 
Normal 0       
Abdomen bleu 1       
Extrémités pâles 2       
Température en surface 
Chaud 0       
Indécis 1       
Froid 2       
Reflexes/réponse au toucher 
+++ 0       
++ 1       
+ 2       
- 3       
Comportement dans sa cage 
Normal 0       
Apathie 1       
Léthargie 1       
Rigidité 2       
Léchage 
++ 1       
+ 0       
- 1       
Comportement alimentaire 
Mange ++, boit ++ 0       
Mange +, boit + 1       
Mange -, boit - 2       
Mange --, boit -- 3       
Tremblement + 0       - 1       
Posture voutée - 0       + 1       
Déshydratation 
- 0       
+ 1       
++ 2       
Vomissement 
- 0       
+ 1       
++ 2       
Excréments Normaux 0       Diarrhée 1       
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Toux Non 0       Oui 1       
Examen lié à l'expérience         
Infection de plaie 





      
Inflammation avec 
exsudat 4 
      
Ulcération 6       
Croissance tumorale interférant avec 
les fonctions vitales 
Non  0       
Oui 6       
 Total        
 
L’animal est euthanasié quand un score de 6 est atteint. 
La grille de scores sera adaptée suivant les observations des animaux lors du projet pilote.  
 
 
- fréquence : Quotidiennement 
- personne(s) en charge du suivi quotidien : Eléonore Longton, Christoph Schifflers 
 
 
Des points limites ont-ils été déterminés?      oui   non 
 
Si oui, veuillez les préciser ? 
- Perte de poids excédant 20 % du poids total initial 
- Croissance tumorale interférant avec les fonctions vitales 
- Ulcération à l’endroit de la tumeur 
- Un score 6 dans la grille de score 
- Volume tumoral insuffisant (inférieur au volume tumoral attendu en fonction du groupe 
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VI. Projet expérimental  
 
A. Recherche envisagée 
 
Le traitement des cancers tête et cou reste un énorme défi médical sans nette amélioration majeure sur 
la survie des patients. Les études cliniques récentes utilisant des anticorps dirigés contre les immuno-
modulateurs ont démontré des résultats prometteurs mais leur succès est limité par les propriétés 
immunosuppressives du microenvironnement tumoral. Les macrophages associés aux tumeurs (TAMs) 
représentent les cellules immunitaires les plus abondantes dans la tumeur et plus de 70% d’entre eux 
présentent un phénotype de type M2 avec une activité immunosuppressive importante. En 
conséquence, reprogrammer les TAMs vers un phénotype M1, avec des propriétés anti-tumorales et 
immuno-stimulantes, serait un moyen efficace d’améliorer l’efficacité de ce type d’immunothérapie. 
La radiothérapie à l’aide de rayons X semble capable d’augmenter la destruction des cellules 
cancéreuses par le biais du système immunitaire. En effet, des résultats préliminaires in vitro montrent 
que l’irradiation par photons repolarise les TAMs vers un phénotype M1 anti-tumoral. Cependant, rien 
n’est connu concernant les effets d’un traitement par photons combiné à une immunothérapie utilisant 
des anticorps anti-PDL1 dans les tumeurs tête et cou. Dans ce travail, nous allons irradier des modèles 
in vitro appropriés ainsi que des modèles murins de tumeurs, afin d’initier la conversion des TAMs en 
macrophages de type M1. Nous étudierons également in vivo la possible synergie de l’irradiation avec 
un traitement d’immunothérapie utilisant des anticorps anti-PD-L1. In vivo, différents paramètres 
seront investigués, notamment le nombre et le phénotype des macrophages et des cellules T dans les 
tumeurs. Les résultats pourront guider des approches de médecine personnalisée en révélant des 
composants du microenvironnement tumoral qui influencent la réponse aux traitements. Les résultats 
préliminaires in vivo de l’irradiation par photons pourraient aussi nous permettre d’envisager une 
comparaison avec une irradiation par protons, technique d’irradiation prometteuse. En effet, des 
résultats préliminaires montrent que l’irradiation par protons altère le phénotype M2 de macrophages 
humains en culture.  
 
B. Place de l’expérience dans le cadre de la recherche envisagée (objectifs)  
 
- Schéma expérimental chronologique (différentes étapes de l’expérience) 
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- Description précise de chaque étape de l’expérience 
 
Injection des cellules : 
Les souris C3H/HeOuJ âgées de 5 à 6 semaines seront hébergées dans l’animalerie centralisée de 
l’extension biologie (L1900631). Après 1 à 2 semaines d’adaptation à leur environnement, les souris 
seront anesthésiées par inhalation d'isoflurane en utilisant la table d’anesthésie disponible à 
l’animalerie centrale. Pour cela, elles seront déposées dans une chambre à induction propre reliée à 
l'appareil d'anesthésie. L'isoflurane sera ajusté 3-4 % et le débit d’oxygène à 0,8-1,5 L/min. Les souris 
seront ensuite posées une plaque chauffante, préchauffée à 37°C afin de maintenir leur température 
corporelle constante.  La suspension de cellules tumorales SCC-VII (250 000, 500 000 ou 1 000 000 
de cellules cancéreuses, sur base du projet préliminaire, suspendues dans 150 µl de PBS) sera injectée 
à la souris en sous-cutanée au niveau du flanc droit. En cas de signes de douleur, une administration 
d’analgésique sera réalisée par injection sous-cutanée de buprénorphine (0,05 mg/kg). 
La taille de la tumeur sera contrôlée quotidiennement à l'aide d'un pied à coulisse. 
 
Suivi des souris : 
Les souris seront examinées quotidiennement afin de vérifier que les points limites de l’expérience ne 
sont pas atteints : 
- Perte de poids excédant 20 % du poids total 
- Tumeur interférant avec les fonctions vitales 
- Ulcération à l’endroit de la tumeur 
- Un score ≥ 6 dans la grille d’observation établie 
 
Si un de ces points limites est atteint, la souris sera euthanasiée. 
 
Irradiation par rayons X 
Une fois la taille tumorale souhaitée (basée sur le projet préliminaire) atteinte, après 2 à 4 semaines, les 
souris (par groupes de 3 souris) seront anesthésiées par un mélange de Kétamine et Xylazine 
(100mg/kg et 10mg/kg, en intra-péritonéal). Elles seront ensuite mises dans une cage de transport qui 
sera emballée d’un sac plastique opaque et transportées au LARN. Dans le générateur, la souris sera 
placée sur un gel préchauffé à 37°C et placée sous un portoir couvert par une plaque en plomb (mise 
au point dans le projet préliminaire) de manière à ce que le trou de 1 cm de diamètre dans la plaque se 
trouve juste au-dessus de la tumeur, afin de limiter l’exposition aux rayons X uniquement à la tumeur.  
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Lorsque la masse tumorale aura atteint la taille souhaitée, ou 72 heures après l’irradiation, les souris 
recevront une injection intra-péritonéale d’anticorps anti-PDL1 (10 mg/kg).  
Azad A, Yin Lim S, D'Costa Z, Jones K, Diana A, Sansom OJ, et al. PD-L1 blockade enhances 
response of pancreatic ductal adenocarcinoma to radiotherapy. EMBO molecular medicine. 2016. 
 
Euthanasie : 
Les souris seront euthanasiées 72 heures après l’irradiation. Pour ceci, une anesthésie générale via une 
injection intra-péritonéale de Kétamine et de Xylazine (100 mg/kg et 10 mg/kg, I.P.) (suivant le 
protocole validé ANIM PO 0007 déposé sur la plate-forme SVTA) sera réalisée à l’animalerie 
centrale. Une fois que les souris seront endormies, elles seront transportées au laboratoire de 
physiologie générale en URPhyM (LA 1900055), où une ponction intra-cardiaque sera réalisée pour 
prélever un volume sanguin maximal, qui servira à l’isolation des monocytes périphériques circulants. 
La ponction intra-cardiaque sera suivie d’une dislocation cervicale. Post-mortem, différents tissus 
seront prélevés : la tumeur, ainsi que divers organes lymphoïdes (analyses histologiques) tels que la 
rate, l’intestin (la jonction iléo-coecale), des ganglions lymphatiques et si possible le thymus. Afin 
d’isoler différentes populations cellulaires à partir des tumeurs (TILs et TAMs), celles-ci doivent être 
dissociées et les cellules isolées au plus vite après l’euthanasie des souris et ce en utilisant un 
gentleMACS dissociateur. Considérant que la dissociation tumorale et l’isolation des cellules doivent 
être effectuées le plus rapidement possible et nécessitent un l’équipement uniquement disponible au 
laboratoire de physiologie générale, les euthanasies doivent avoir lieu au laboratoire de physiologie 
générale. L’anesthésie générale (Kétamine/Xylazine) sera cependant réalisée à l’animalerie centrale ce 
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VII. Sécurité des chercheurs et de l’environnement  
(Ce domaine ne relève pas de la compétence de la commission d’éthique pour l’expérimentation animale. Il s’agit ici 
d’attirer l’attention sur la nécessité éventuelle de consulter le service de sécurité de l’institution). 
 
A. Des produits dangereux sont-ils utilisés ?  Oui  Non 
 - produits physiques (radioactifs…)  Oui  Non 
 
 Si oui, contacter le service radioprotection (Prof. S. Lucas) 
 
 - produits chimiques (toxiques…)  Oui  Non Si oui, contacter le 
Prof. S. Laners 
  
B. Le projet implique-t-il l'utilisation : 
  - d'organismes pathogènes (bactéries, virus, parasites, …)    Oui  Non 
 Si oui, à quelle classe de risque appartiennent-ils :                1           2          3 
 
 - d'organismes génétiquement modifiés                Oui  Non 
 
Si oui à l'une de ces deux questions, contacter S. Loret pour établir le dossier de biosécurité le cas 
échéant.  
 
VIII. Déclaration du Maître d’expérience et du Directeur du laboratoire 
 
Titre de l’expérience : Etude de la reprogrammation des macrophages tumoraux par irradiation 
avec des photons afin d’amplifier l’effet d’anticorps ciblant l’immunomodulateur PD-L1 sur des 
tumeurs murines d’origine ORL 
 
Laboratoire : Unité de Recherche en Biologie Cellulaire (URBC)-Narilis- Faculté des Sciences                          
 
Signatures et dates : 
Cette signature suppose que le maître d’expérience et le directeur du laboratoire reconnaissent leur 
pleine responsabilité et leur accord avec les procédures décrites ci-dessus. 
Les signataires en signant ce document : 
- s’engagent à respecter toutes les modalités décrites dans ce projet; 
- acceptent de soumettre une adaptation  au dossier pour analyse à la commission d’éthique si à 
un moment quelconque de cette expérience, un changement dans l’utilisation doit être apporté ;  
- confirment que les personnes impliquées dans cette étude possèdent la formation adéquate en 
ce qui concerne les conditions de bien-être animal et d’expérimentation animale 
 
 
	
